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Abstract 
Novel Cyclo Deoxynucleoside: Synthesis and Evaluation 
 
Hongchuan Yu 
 
Nucleic acids are essential biological molecules for life. For example, 
deoxyribonucleic acid (DNA) is the main genetic information carrier; ribonucleic acid 
(RNA) plays a critical role in translation and transcription. These characteristics place 
nucleic acids as the fundamental genetic materials of a living system. Since over a 
century ago, intensive attempts have been made by researchers to study the nucleic acid 
properties. For chemists, it is particularly interesting and important to understand the 
relationship between structures and properties of nucleic acids. For instance chemical 
modifications can alter stability of nucleic acids, and consequently influence their 
biochemical behaviors. 
In this work, we began by investigation of a 5’,6-cyclo-modified nucleic acid 
resembling the product of DNA oxidation, and then developed a library of cyclo-
modifications. Our research on their structures and properties indicated that by installing 
cyclo-modifications we might be able to add some properties, which were not observed in 
nature to nucleic acids.  
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1.1 Discovery of nucleic acids 
Gregor Mendel opened the door to the field of genetics in 1857 by performing his 
famous experiment of breeding pea plants. People came to realize that heredity was 
defined by substances inside the human body. In 1869, Swiss physician Friedrich 
Miescher1 discovered and isolated a kind of white, slightly acidic chemical from 
discarded surgical bandages. He named it “nuclein”, which we now know as the 
chromosome. Nine years later, Albrecht Kossel a German biochemist first isolated the 
non-protein containing nucleic acid from “nuclein”, and later isolated the five primary 
components of nucleic acids. He was awarded the Nobel Prize for Physiology or 
Medicine in 1910 for this work. 
  
 
Figure 1.1 Five nucleobases existing in DNA and RNA. Among them adenine and 
guanine are purine derivatives, and cytosine, thymine, and uracil are pyrimidine 
derivatives. 
 
In the early 20th century, Phoebus Levene identified that nucleobase,2 sugar, and 
phosphate are the three units that form a nucleotide. (Fig. 1.1 showed the five nucleobase 
structures and numbering) Levene also suggested that DNA consisted of a linear linkage 
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of nucleotide3 through a phosphodiester bond. This discovery facilitated the rough sketch 
of the structure of DNA. Then, Todd successfully synthesized four deoxynucleoside 
monomers,3 and found that their structures are β-glycosylated deoxyribonucleosides. His 
finding supported the linear structure hypothesis. (As shown in Fig. 1.2) 
 
Figure 1.2 Demonstration of DNA and RNA single strand linkage through a 
phosphodiester bond. 
 
As the functions of those chemicals were under investigation, Flemming 
concluded that “inheritance may, perhaps, be affected by the physical transmission of a 
particular chemical compound from parent to offspring” by staining nuclein at the certain 
stages of cell division. In 1943, the Avery–MacLeod–McCarty4 experiment showed that 
DNA is the substance that invokes bacterial transformation; this experiment provided the 
first clear suggestion that DNA is the genetic information carrier rather than protein 
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which was, at that time, widely believed to be. Their conclusions were further confirmed 
in the Hershey–Chase5 experiment with T2 phage, in 1952.   
In 1953 Watson and Crick6 published their famous article in Nature, suggesting 
that the DNA structure is a double helix. They determined this by using the X-ray fiber 
diffraction patterns developed by Franklin and Wilkins7, 8 and Chargaff’s9 rule on nucleic 
base complimentarity. This model portrayed a double helix in which hydrophobic 
nucleobases were sequestered from water by pairing on the inside, whereas the 
hydrophilic phosphates remained on the outside of the helix. Crick used this structural 
information to state the central dogma of molecular biology: “The central dogma of 
molecular biology deals with the detailed residue-by-residue transfer of sequential 
information. It states that such information cannot be transferred back from protein to 
either protein or nucleic acid.”10 All of these discoveries, and the work that made them 
possible, brought nucleic acid research and biochemistry to a new era. 
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1.2 Nucleic acid structures 
 
Figure 1.3 Deoxyadenosine monophosphate as an example of a mono nucleotide. 
 
Nucleic acids are consisting of nucleotides. A nucleotide is composed of three 
parts: a nucleobase (purine or pyrimidine shown in Figure 1.1), a five-carbon sugar 
(either ribose or 2'-deoxyribose), and a phosphate group. The nucleobases are essential 
for base recognition by hydrogen bonding to each other in a specific pattern. The 
nucleobases are attached to the ribose sugar containing a 5’ phosphate group. This 
phosphate is connected via a phophodiester linkage to a neighboring nucleoside sugar (at 
the 3’ position), and this forms the backbone of nucleic acids. The phosphate group not 
only forms this linkage between adjacent nucleotides, but also maintains a negative 
charge, which makes the phosphoribose backbone kinetically stable. Figure 1.3 is an 
example of a mononucleotide. The numbering of the base was shown in Figure 1.1. The 
numbering of the sugar and the phosphate and the torsion angle assignments of the 
nucleotide are shown below, as adopted from Saenger’s book11(Figure 1.4). 
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Figure 1.4 Torsion angles of nucleotide chain. Image is adopted from Saenger11.
 
From Fig. 1.4, with changes in angle χ, the base can adopt two main orientations 
called syn and anti. In syn, the bulk parts of the heterocycles are pointing toward the 
sugar ring, whereas the anti conformation is the opposite. The definitions of syn and anti 
are given by IUPAC as shown below (Fig. 1.5). 
 
Figure 1.5 Definition of syn and anti conformational angles.12 The figure on the left is 
showing the definitions for a purine base, the χ angle is measuring O4’-C1’-N9-C4; the 
figure on the right is showing the definitions for a pyrimidine base, where the χ angle is 
measuring O4’-C1’-N1-C2. 
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Nucleic acids usually form a duplex under native conditions. The common 
conformations of duplex are right-handed A-form, B-form, and left-handed Z-form. For 
DNA, B-form is the most common and stable conformation in nature. B-form DNA is a 
23.7 Å-diameter right-handed double helix that extends 34 Å per pitch which is ideally 
made up of 10 base pairs.13 The planes of hydrogen-bonded base pairs are nearly 
perpendicular to the helix axis. These base pairs occupy the center of the helix while the 
hydrophilic sugar-phosphate backbone winds around and form the major and minor 
grooves.  In B-form DNA, the base is held in an anti conformation and forms a Watson-
Crick base pair. (Fig. 1.7) In this base pair pattern A-T and G-C base pairs have the same 
width. 
 
Figure 1.6 Three major helical structures have been observed by crystallization of DNA. 
A-form and B-form are right-handed and Z-form is left-handed. B-form is the most 
preferable conformation of native DNA. Image is adopted from Saenger11. 
Major Groove 
Major Groove 
Minor 
 Groove 
Minor 
 Groove 
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            A-Form DNA                           B-Form DNA                         Z-Form DNA 
Figure 1.7 Top views of A-form, B-form, and Z-form DNA.14 
 
Figure 1.8 The Watson-Crick base pairs first suggested by Watson and Crick in 1953.6 R 
represents the ribose sugar of the nucleotide, correct tautomerizations make two hydrogen 
bonds in an A-T base pair, and three hydrogen bonds in a G-C base pair.  
   
Native DNA adopts A-form under dehydrating conditions. A-form DNA is a 
wider and flatter right-handed helix than B-form. A-form DNA has a 26 Å diameter, 11 
bases in each helical turn, and a 34 Å pitch. Nucleobases in A-form DNA are located 
further from the axis of the helix than in B-form, which makes A-form DNA hollow in 
the center. (Fig. 1.7)  The base pairing pattern and glycosidic bond arrangement are the 
same as in B-form.15 The most significant difference between nucleotides in A-form and 
B-form is the sugar puckering modes. (Fig. 1.9) In A-form, the sugar adopts a C3’-endo 
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form, whereas a B-form sugar adopts a C2’-endo. The differences of sugar puckering 
influence the distance between adjacent phosphate groups in sequences. Crystal 
structures have shown that the adjacent phosphate distance is about 5.9 Å in C3’-endo 
sugar, and 7.0 Å in C2’-endo sugar (Fig. 1.10). C3’-endo makes the sugar more compact 
along the helical axis, while the C2’-endo makes the sugar more spread out along the 
helical axis. As a consequence, A-form DNA has a narrow and deep major groove and a 
wide and shallow minor groove; B-form DNA has a wide and deep major groove and 
narrow and deep minor groove.    
 
Figure 1.9 Definition of sugar puckering modes. Knowing the geometry associated with 
the sugars tells you that a five-membered carbohydrate ring is not able to keep all atoms 
in one plane, and the most stable state is as an envelope (1.2 and 1.3) with four atoms in a 
plane and the fifth out of the plane by about 0.5 Å. Changing from one envelope form to 
another results in twist forms, which keep two adjacent atoms displaced on opposite sides 
of the C1’-O-C4’ plane. State 1.1 is the starting position with five atoms in the same 
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plane which has never been observed. State 1.2 is the envelope C3’-endo; state 1.3 is the 
envelope C2’-endo; state 1.4 and 1.5 are twist forms. Image is adopted from Saenger11. 
 
 
Figure 1.10 Crystal structures of C3’-endo (Shown on left) A-form deoxynucleotide and 
C2’-endo (Shown on right) B-form deoxynucleotide. 
 
Z-form DNA (Shown in Fig. 1.6 right) is a left-handed helix, only observed in 
certain sequences such as poly d(GC) - poly d(GC), poly d(AC) - poly d(GT), and under 
highly dehydrating conditions. This structure was first revealed by Andrew Wang and 
Alexander Rich16. Z-form DNA has 12 Watson-Crick base pairs in one turn, and a pitch 
of 45 Å. In 2005 a crystal structure of a B- to Z-DNA junction was published which 
helped us better understand the potential role of Z-DNA in cells.17 B-Z junctions at two 
ends are required for Z-DNA to form. Two years later, the same group described Z-RNA 
forming from a normal A-RNA double helix.18 Z-form DNA is still hard to study because 
it rarely exists as a stable double helix. It usually appears as a transient duplex that is 
occasionally induced by other biological activity.19 
5.9 Å 
7.0 Å 
C3’ 
C2’ 
C2’ 
C3’ 
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Native double-stranded RNA exists in certain types of viruses, behaving as 
genetic material. But synthetic RNA is usually single stranded. Nevertheless, single-
stranded RNA would be able to fold back on itself to form a hairpin, which includes a 
double-stranded stem and a single-stranded loop. In most situations duplex RNA would 
not be able to adopt a B-form helix, because the 2’ hydroxyl group forces a C3’ endo 
conformation of the ribose.  The parameter of A-from RNA is slightly different from A-
form DNA: one helical turn of A-RNA has 10.6 base pairs rather than 11in A-DNA; the 
pitch of one A-RNA turn is about 26.5 Å rather than 28 Å in A-form DNA. (Fig. 1.11 
shows an example of tRNA) 
 
Figure 1.11 The crystal structure of RNA double strands in transfer RNA complexed to 
adenosine triphosphate (ATP). Image is adopted from Saenger20 
 
 
Double strand 
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1.3 Biological function of DNA and RNA  
1.3.1 Replication 
Nucleic acids including DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) 
are the essential genetic material for life. The primary function of DNA is the storage and 
transmission of genetic information from one generation to another. Replication is the 
key step of gene transmission. In cell division, replication of DNA in the genome is 
essential to ensure two daughter cells carrying the exact same genetic information as their 
parent. Replication starts from unwinding double-stranded DNA, and then the 
complementary DNA sequence of each strand is generated by connecting 
mononucleotides with a class of enzymes called DNA polymerases.  Because nearly all 
known DNA polymerases can only add a nucleotide to the free 3’-hydroxyl of a 
elongating double-stranded polynucleotide, DNA can only extend in the 5’ to 3’ 
direction.21 Two parental strands are replicated in different ways. Newly synthesized 
DNA strands that extend in the 5’ to 3’ direction are synthesized in the 5’ to 3’ direction 
as usual by a polymerase. The other new stand is also synthesized in its 5’ to 3’ direction, 
however, it can only form small fragments of polynucleotides, called Okazaki fragments. 
(Fig. 1.12) Then those fragments are covalently joined together by the enzyme DNA 
ligase to form the new double stranded polynucleotide, with one original parental 
13 
 
strand.22 DNA replication is never perfectly accurate, a low baseline level of mutation has 
allowed the evolution of various forms of life. 
 
Figure 1.12 A schematic outline of DNA replication and Okazaki fragments.23 
 
1.3.2 Transcription and translation 
The genetic information is stored as DNA in the nucleus. Only through the 
processes of transcription and translation, can genetic information be transferred into 
protein and direct the behavior of a biological system. Transcription is the process of 
creating a complementary RNA strand from the DNA. During transcription, duplex DNA 
sequence is unwound and enzymes break the base pairing between complimentary double 
strands of DNA. Then RNA polymerase, which produces RNA, adds matching 
ribonucleotides to produces an RNA sequence complimentary to the template DNA.  
After the sugar-phosphate backbone of the new RNA, called messenger RNA (mRNA), is 
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formed, hydrogen bonds of the untwisted RNA-DNA hybrid are broken, freeing the 
newly generated RNA strand. 24 At this point, the genetic information coded as mRNA is 
ready to facilitate protein expression. 
Translation is a process which expresses genetic information held by mRNA into 
protein. In prokaryotes, translation occurs in the cytoplasm, the large and small ribosome-
like subunits bind to the mRNA. In Eukaryotes, translation occurs across the endoplasmic 
reticulum membrane, in a process called vectorial synthesis.25 The ribosome gathers up 
the genetic information as mRNA and recruits the activated amino acids via their 
transporter, tRNA. Through the decoding process, amino acids held by tRNA are 
connected to generate polypeptides. Folding of the mature polypeptides completes the 
translation of the genetic information. The discovery of catalytic RNA in the ribosome 
suggests that RNA could not only perform as a genetic information translator but also as 
a catalytic material similar to an enzyme. Now, more and more catalytic RNAs are under 
investigation.26-29 
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1.4 Factors affecting duplex stability 
Nucleic acid duplex formation and dissociation is an essential process in many 
biological functions, such as DNA replication, translation, and RNA interference. The 
influence of duplex stability to cell behavior has been intensively investigated.30-32 The 
most widely studied factors affecting nucleic acid duplex stability are hydrogen bonding, 
base stacking, and ionic effects. Other factors have also been investigated by a number of 
labs.33-38 
 
1.4.1 Hydrogen boding 
Every nucleobase has hydrogen bonding donor and acceptor sites, so bases are 
able to pair with each other. As we stated before, Watson-Crick base pairs are the most 
common pattern while other base pair patterns exists as well, like the Hoogsteen base 
pairing and wobble base pairing. (Fig. 1.13) The free energy associated with a hydrogen 
bond is usually in the range of 1 kcal/mol to 5 kcal/mol. In an aqueous environment, 
forming a hydrogen bond is not always energetically favorable, because water molecules, 
which are also good hydrogen bond donors and acceptors, are exchanged in the process. 
In the situation of base pairing, water-nucleobase hydrogen bonds are broken, while 
nucleobase-nucleobase hydrogen bonds are installed. These steps seem to be 
enthalpically disfavored, but if the enthalpy gain for newly formed water-water hydrogen 
bond is incorporated, the total effects make it enthalpically favorable.39 In terms of 
entropy, forming a base pair would limit the rotation and vibration of bases, which is 
16 
 
entropically unfavorable. However, the entropy gain of the free water molecules is highly 
favorable.  
In order to evaluate the energy contribution of hydrogen bonding in duplex 
formation, researchers have done comparison studies with base pairs that differ only in 
the number of hydrogen bond interactions. Comparisons of doubly- or triply-H-bonded 
base pairs were investigated.40, 41As an example, energy difference between I-C (inosine-
cytosine) pairs and G-C pairs revealed a free energy of -0.7 to -1.6 kcal/mol for the third 
hydrogen bond. However, the energy studies of stacked G-C base pairs suggested that the 
three hydrogen bonds of the pair contribute less than three times this amount because of 
the cooperative effect. Kool’s research revealed  -0.25 kcal/mol free energy gain for each 
hydrogen bond in studying a six-base pair duplex of G-C pair system.42 Furthermore, 
nonpolar DNA base mimics (2,4-difluorotoluene replaced native base T, 4-
methylbenzimidazole replaced native base A) were incorporated into synthetic DNA 
oligomers to investigate the energy of hydrogen bonds.43-45 These experiments showed 
quite different outcomes when the position of the mimics changed: when the modification 
was located in the middle of a double strand, it destabilized the duplex by 1.6 kcal/mol45; 
when the modification was located at the edge, it stabilized the duplex.  The 
hydrophobicity of these nonpolar bases accounted for the relatively large disturbance of 
incorporation, and researchers suggested that the overall structure strongly affects the 
measured strengths of noncovalent interactions such as individual hydrogen bonds.46 
17 
 
 
Figure 1.13 Common base-pairing in nucleic acids.  
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1.4.2 Base stacking 
Previous studies have revealed the fact that nucleic acid base stacking is a strong 
contributor to the overall stabilization of the double helix.  Most of the time this might be 
the dominant factor.47, 48 Base stacking is actually composed of several noncovalent 
forces11, 49 including London dispersive forces, electrostatic effects, and solvation effects.  
Electrostatic effects in nucleobase stacking have received the greatest attention. 
Hunter and Sanders proposed an early model for pi-pi stacking interactions,50 which used 
a simple mathematical model based on atomic charges and relative orientations. In this 
model they considered that electrostatics were dominant in substituent effects. In 1994, 
after a series of experiments Newcomb and Gellman compared two aromatic groups 
connected by a 3-atom linker that only allows the two aromatic rings to be close to 
parallel arrangements (Fig. 1.14). Adenyl derivative compounds were found to form 
stable stacking, whereas napthyl derivatives did not stack well. They reasoned that the 
solvation and London dispersion forces acted similarly to both di-naphthyl derivatives 
and di-adenyl derivatives. Thus, the observation could only be accounted for by partial 
atomic charges, which was responsible for adenyl–adenyl stacking forming in water. 51 
But a follow-up study gave the opposite result. Friedman and Honig reported that the net 
effect of adenine partial atomic charges in the AMBER 52 force field would resist the 
stacking in water.53 In addition, from calculations, other researcher concluded that the 
stability of the stacked nucleic acids originates not in electrostatic interactions but in 
electron overlap.54-56 It seems that electrostatic effects are significant factors in 
influencing variations for many different base pairs and structures. But these effects are 
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considerably dependent on the arrangement of the neighboring base. However, generally 
electrostatic effects contribute a small portion in the stabilization of random DNA.42 
 
Figure 1.14 structures of compound investigated in Newcomb and Gellman’s experiment 
the 1.6: bis-adenyl, 1.7: bis-naphthyl and 1.8: mixed adenyl-naphthyl 51 1.6 is the most 
stable structure, then 1.8 is the second, and 1.7 is least stable.  
Since theoretical calculations showed that London dispersive forces were found to 
have major stabilization effects only in isolated bases and base pairs in vacuum,57-60 
solvation effects became an important force to study. A study of stacking free energy of 
nucleobases and other nonpolar aromatic rings was performed, and it showed that 
nonpolar aromatic rings were more favorable in stacking than their nucleobase 
counterparts. 49 This result suggested that hydrophobic interactions play an important role 
in base stacking in aqueous environments. Meanwhile, many theoretical calculation 
studies confirmed this conclusion through a free energy point of view.61-64  
A comprehensive set of data for the stacking of all four natural bases with all four 
possible neighboring bases was investigated.47 In general, the purines provide stronger 
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base stacking than the pyrimidines, and the neighboring base has a very significant effect 
on stacking. This might be explained by different electrostatic interactions between 
varied pairings of the two bases directly involved in the stacking interaction and variable 
polarizabilities of those neighboring bases.65 Marmur and Doty’s study showed that DNA 
polymer stability has a linear relationship between the G-C content of the polymer and its 
melting temperature.66 
 
1.4.3 Ionic effect 
The anionic phosphate in the backbone of nucleic acid sequences requires charge 
neutralization for the formation of stable structures because of the electrostatic repulsion. 
Cations play a critical role in minimizing the repulsion and facilitating the duplex 
formation of nucleic acids. Both monovalent and divalent ions can play the same role to 
stabilize nucleic acid structure by nonspecific interactions with the anionic backbone. A 
linear free energy relationship for duplex thermostability of oligonucleotides has 
previously been shown. 67 This relationship fit for not only monovalent cations but also 
divalent cations. A notable phenomenon is that divalent cations provide more 
stabilization than the same concentration of monovalent cations.  Most monovalent 
cations (eg. Na+, K+, Cs+) stabilize a duplex to the same extent depending on salt 
concentration. Lithium cation showed the highest efficiency in duplex stabilization.68 
Researchers claimed the higher ionic character of lithium cation as an explanation.69  
Divalent cations, especial smaller atomic number atoms are much more efficient in 
stabilizing nucleic acid duplexes. Among them magnesium cation was the most effective 
cation. The abilities to stabilize a duplex usually follow this order: 
21 
 
Mg2+>Ca2+>Mn2+>Ba2+>>Li+>Na+≈K+≈Cs+.70 Beside the general stabilization, 
magnesium cations also played a important role in RNA folding in cell metabolism. 71 
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1.5 Nucleotide modifications to alter duplex 
stability 
Recent developments have allowed researchers to modify the structure as well as 
the atomic make-up of native nucleotides. Until now numerous modifications have been 
investigated at nearly every active site of nucleotides, here we simply classify them into 
phosphate modification, base modification, and sugar modification.  
 
1.5.1 Phosphate modification 
Modifications of the phosphate is the simplest modification to achieve 
synthetically for nucleotides, and was one of the first modifications to be investigated.72,73  
Through phosphate modification, lipophilicity can be increased to improve uptake, and 
decrease the rate of degradation by nucleases, which are designed to degrade phosphate 
esters. These modifications help oligonucleotides survive in biological environments and 
also to cross the cell membrane. Phosphate modification is usually achieved by replacing 
the phosphorous-oxygen bond with another chemical bond, which is able to reduce the 
negative charge at phosphate backbone. 
Methylphosphonate (Fig. 1.15) is one of most extensively studied examples. It 
was first introduced by Miller in 1979,74 and the synthesis was based on modifications of 
the triester approach.75-80 The following study showed that this compound was able to 
incorporate into oligonucleotides.81 After the methyl substituent on phosphorus was 
investigated, phenyl phosphonate75 and 4,4’-dimethoxytriphenylmethanephosphonate 
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were prepared.82 Moreover, a (difluoromethyl) phosphonate was synthesized which 
would mimic the natural oxygen atom better.83 
Phosphotriesters (Fig. 1.15) are another type of phosphate modification. These 
compounds were used even before the methylphosphonates.84This modification could 
also provide a nonionic backbone, and it seemed to be synthetically more convenient. 
The drawback of this type of modification was that the triester functional groups were 
labile during the basic conditions used in cleaving the oligomer from the solid support.  
As a result, most studies were limited to oligonucleotides containing only a single triester 
or only poly (dT).85 Improvements have been made to facilitate the modification: 
methanol and tosyl chloride were used to esterify internucleoside phosphates after each 
coupling to yield short modified sequences.86, 87 This method has been proven to be 
effective by other laboratories.88 
Since phosphorous-oxygen bonds were referred to as vulnerable sites of 
oligonucleotides,89 researchers were looking to replace the oxygen atoms.  Researchers 
found that oligonucleotide analogs (Fig. 1.15) in which the non-bridging phosphate 
oxygen atoms are replaced with other chalcogen atoms (such as S or Se) have stronger 
resistance to nuclease dissociation.90-92 This modification could be reached by sulfur 
oxidation of oligonucleotide phosphite. But in this way, single replacement 
phosphorothioate was achieved, which results in many P-chiral diastereoisomers,93 and 
these compounds performed differently even with the same biological target. So 
improved modified oligonucleotide analogs, in which both non-bridging oxygen atoms of 
the backbone phosphate moiety were replaced by sulfur atoms, were synthesized and 
investigated. Like their predecessor, disulfur modified nucleotides (Fig. 1.15) showed 
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complete resistance to hydrolysis by various nucleases. Meanwhile they were shown to 
be able to activate RNase H in vitro, strongly inhibit human immunodeficiency virus 
reverse transcriptase, and induce B-cell proliferation and differentiation.94, 95 
Other modifications have also been used in oligonucleotides, such as 
phosphoramidite (Fig. 1.15) at the non-bridging phosphorous-oxygen position and 
pentavalent phosphorus.96-99 But most of them were not examined as extensively as the 
previous examples. 
 
Figure 1.15 Some examples of phosphate modification: 1.9: normal nucleotide linkage. 
1.10: Methylphosphonate. 1.11: Phosphotriesters. 1.12: Single sulfur replaced non-
bridging phosphate oxygen linkage (P-chiral). 1.13: Double sulfur replaced non-bridging 
phosphate oxygen linkage (P-achiral). 1.14: Phosphoramidite replaced non-bridging 
phosphorous-oxygen linkage.100 
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1.5.2 Base modification 
Modifications on nucleobases can be achieved by a wide range of methods. The 
type of modification on a nucleobase includes atom or group substitution on the 
heterocycle, the addition of extra atoms or groups, and structure modification. 
Nucleobase modifications can change properties such as the aromaticity or the affinity of 
the base to water or other molecules.  
In 1972 2-amino-deoxyadenosine was synthesized by Christensen and Broom.101 
This modification installed an extra hydrogen bonding site to adenosine, which made it 
have potentially three hydrogen bonding sites. Research showed that this modification 
resulted in a net free energy gain from base pairing, and better recognition.102 
Substitutions on the nucleobase were another way to make modifications. When the 5-
methyl group of thymidine was substituted by halogen little effect was observed, and 
methoxy-ethoxy-methyl group substitutions would decrease the duplex stability. 
Extensive studies have been done, and are listed below.103 (Scheme 1.1) 
 
Entry Modification ∆Tm per modification (comparing to parent 
DNA) 
1.15 -R1 -R2 Seq.1 Seq. 2 Seq.3  Seq.4  Seq.5 Seq.6 
1.16 -H -H -0.6 -.32 -0.2 -0.4 +0.1 -0.3 
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1.17 -F -H -0.2      
1.18 -Br -H +0.3      
1.19 -I -H -0.1      
1.20 -C=C-CH3 -H +0.9 +2.6 +1.7 +2.1 +2.6  
1.21 -CH2-O-C2H4-O-CH3 -H -1.0 -2.2 -1.6  -1.2  
1.22 -H -CH3 -3.9      
1.23 -CH3 -CH3 -3.3      
1.24 5-6 propyl bridge  -2.7 -1.3     
Seq.1: 5’-(tCCAGGtGtCCCGCAtC)-3’ 
Seq.2: 5’-(CTCGTACCtTTCCGGTCC)-3’  
Seq.3:5’-(CTCGTACttttCCGGTCC)-3’  
Seq.4: 5’-(GCGtttttttttttGCG)-3’ 
Seq.5: 5’-(TTTTtCTCTCTCTCT)-3’ 
Seq.6: 5’-(tttttCtCtCtCtCT)-3’ 
t represents a modified thymidine nucleoside. 
Scheme 1.1 Effect of 5 or 6 pyrimidine substitution on ∆Tm. Data from Freier.104 
 
In Scheme 1.1, 1.17-1.19 are all halogen substituted, they have similar stability as 
native DNA, which show that halogen substituents resemble native DNA as well. 1.21-
1.24 show significant destabilization; these could be explained by the bulky sizes, which 
disturb base stacking.  Only entry 1.20 stabilized the duplex because it enlarges the 
aromatic system, which makes base stacking more favorable.105  
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Purine heterocycles have also been modified, resulting in improved duplex 
stability. 7-halo-7-deaza purines were one type of the most stabilizing purine 
modifications.106, 107 Researchers proposed that increased stacking of the modified purine 
rings caused increased duplex stability.104 
 
1.5.3 Sugar modification 
Structures of the sugar moiety of nucleotides control nucleic acid conformation. 
The largest difference between A-form and B-form nucleotides is the conformation of the 
ribose sugar. Saenger claims that the sugar pucker is the essential distinction between A-
form and B-form polynucleotide helices.11 Multiple examples have been developed, 
Locked Nucleic Acids (LNA), Peptide Nucleic Acids (PNA), and Glycol Nucleic Acids 
(GNA), which were successful in manipulating the nucleic acid behavior.108-115 
The sugar rings of oligonucleotides are 2’-deoxyfuranose or furanose.  C-3’-endo 
and C-2’-endo are two major, interchangeable conformations, where the C-3’-endo sugar 
ring conformation is maintained in A-form and C-2’-endo sugar conformation is 
maintained in B-form.11 Studies have shown that an electronegative substituent at the 2’ 
position would increase the electronegativity of the C3’-endo conformer. 2’-substituted 
analogs of 2’-deoxynucleotides such as fluoro, amino, methoxy, allyloxy, have been 
introduced in elucidating hammerhead ribozyme behavior.116-119 2’-Fluoro- and 2’-
difluoro-2’-deoxyuridine–containing oligonucleotides have been shown to resist the 
excision repair activity of the enzyme of human G/T glycosylase120 and resulted in the 
formation of a tight-binding DNA-glycosylase complex. The scheme below shows 
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synthestic path ways routes of monofluoro substitued 2’-deoxynucleoside analogs and 
difluoro substituted 2’-deoxynucleoside analogs. 
 
Reagents and conditions: (i) HMPA, Ph2CO, NaHCO3, 150 oC, 30 min; (ii) HF–pyridine, 1,4-dioxane, 
120–125 oC, 18 h; (iii) Ac2O, pyridine; (iv) 1,2,4-triazole, pyridine, POCl3, rt, 17 h; (v) (a) NH4OH, rt, 4 h; 
(b) NH3/MeOH, rt, 12 h. 
 
Scheme 1.2 Synthesis of monofluoro substitued 2’-deoxynucleoside analogs for 
deoxyuridine, deoxythmidine, and deoxycytidine.121 
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Reagents and conditions: (i) BrF2CCO2Et Zn, 55 oC, 30 min; (ii) Dowex 50W-X12, rt. 4 d; (iii) TBSTf, 
Lutidine, rt, 12 h (iv) DIBAL-H, -65 oC 2 h; (v) MsCl, Et3N, rt, 12 h; (vi) (a) 
((trifluoromethanesulfonyl)oxy)trimethylsilane, 41 oC, 15 h; (b) AG 50W-X8, rt, 12 h. 
 
Scheme 1.3 Synthesis of difluoro substitued 2’- deoxycytidine analogs.122 
 
Another sugar modification site is the furanose ring oxygen. It could be replaced 
by a methylene group to give carbocycle analogs, or by a sulfur atom to give 4’-
thiofuranose. The carbocyclic analog of thymidine and deoxycytidine have been involved 
in the study of their effect on triplex formation.123 Another carbocyclic analog, 2’-
deoxyadenosine, helped to elucidate the mechanism of action of the MutY protein of E. 
coli, which deletes mismatched deoxyadenosine residues from a DNA substrate.124 
Oligonucleotides containing 4’-thiofuranose modifications have been used to probe 
protein-DNA interactions such as in the EcoRV restriction endonuclease and methylation 
systems.125,126 
2’,4’-bridged nucleic acids are another valuable modification, which has attracted 
a lot of attention in recent years. Locked Nucleic Acids (LNA) are one of these 
modifications. In typical LNA, the bridge is built up by 2’,4’-methylene-oxygen linkages 
(Fig. 1.16). By installing this modification, sugar pucker is preorganized into the C3’-
endo conformation, which would mimic the duplex comformation and make LNA 
including duplex more energetically favorable. LNAs were introduced by several 
independent groups at nearly the same time.113,114, 127-129 Then the structures of LNAs 
were analyzed, and it was confirmed that duplexes existed in the A-form RNA like 
comformation.130-132 The base pairing pattern of LNA resembles native Watson-Crick 
type, which result in the formation of both LNA-DNA and LNA-RNA hybrids. 
Experimental data showed that fully modified LNA oligomers or modified and native 
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mixed oligomers were able to induce very high thermal stability of duplexes toward 
complementary RNA or DNA.129 Studies have shown that when LNA modifications were 
incorporated into double strand DNA duplexes, the original B-form character of the DNA 
duplexes decreases upon incorporation percentage of LNA.133 These facts proved the 
preorganization rather than other effects contribute the most to stabilize LNA containing 
duplex formation.134 
 
Figure 1.16 Structure comparisons of RNA and LNA. 2’,4’-bridge made the sugar 
pucker of LNA similar to the sugar pucker of A-form RNA, and the locking bridge was 
claimed as the main factor to increase its RNA binding affinity.128 
 
While LNA gained research attention, other LNA analogs were also under 
investigation. Wengel and co-workers identified the structure of α-L-LNA, which showed 
nearly the same affinity as normal LNA to target RNA. Whereas the structure of α-L-
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LNA showed more B-form character.135, 136 Besides α-L-LNA, many other patterns of 
LNA linkage were discovered and investigated as shown in Fig. 1.17. 
 
Figure. 1.17 Synthetic LNA Analogs: 1.37: α-L-LNA, similar affinity of LNA in 
targeting RNA.135, 136 1.38: Amino-LNA, less thermal stability than LNA.137 1.39: Thio-
LNA, similar thermal stability as LNA.137 1.40: N-MeO-amino BNA (2’,4’-Bicyclic 
Nucleic Acid), similar thermal stability as LNA, some toxicity found.138 1.41: (S)-cEt 
BNA. 1.42: (R)-cEt BNA. 1.43: (S)-cMOE BNA. 1.44: (R)-cMOE BNA. 1.41-1.44 all 
showed similar thermal stability of LNA, only 1.41 showed an improved therapeutic 
index of antisense.139,140 1.45: Carbo LNA. 1.46: Me-carbo LNA. 1.47: Carbo LNA 
analogs (R1=Me, R2=OH; or R1, R2= Me). (9-11) all showed similar Tm value of 
corresponding LNA, and improved nuclease stability.141  
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Peptide Nucleic Acid (PNA) is another type of sugar modification. It was 
discovered during the 1990s by Nielsen and Buchardt.142 So far, more than 1000 articles 
on PNA have been published with regards to its synthesis, characterization, and 
biological function. The backbone of PNA is made up of repeating N-(2-
aminoethyl)glycine units linked by peptide bonds.143-146 The base of PNA are connected 
to the backbone through methylene carbonyl linkages. PNA is able to form duplexes with 
both DNA and RNA; moreover, because PNA holds no charge on its backbone, it is also 
utilized in triplex research.147, 148 
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1.6 Rigid nucleoside modification 
Rigid nucleoside modifications refer to those modifications that reduce the overall 
flexibility of nucleotides, and have invoked great interest from nucleic acid chemists. 
LNA referred to one type of rigid modification, and it resulted in a great improvement of 
double strand thermal stability.128-130 Researcher’s interests in this class of molecules 
comes from the desire to design a modified sample of biological DNA or RNA so that we 
can manipulate the behavior. We hypothesize that by limiting the motion and angles, we 
may be able to make a duplex of nucleic acids favorable or non-favorable, depending on 
the situation.  
Many examples of rigid modifications have been synthesized and evaluated over 
the past several decades. Most of them could be classified into two major categories. The 
first one, also the most common one, results from installing a structure that makes the 
sugar pucker preorganized, such as LNA and its analogs. The other strategy involves a 
covalent linkage between the sugar ring and the nucleobase. 149, 150 The LNAs were 
previously discussed, so here we focus our attention on the second class of modifications. 
This type of modifications is achieved by covalent connections between the 
carbohydrate and the nucleobase. These molecules provide the potential to achieve an 
even higher rigidity than LNA. As we described before, the ability of LNA to facilitate 
duplex formation mainly derives from its ability to preorganize the sugar pucker to the A-
form.134 This second type of modification might cause similar properties as the LNAs. 
Other than rigidity, these modifications also limit the rotation of the nucleobase over the 
glycosidic bond. Normal nucleobases adopt an anti conformation when they are 
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incorporated into most native Watson-Crick base pairing. So, most of the nucleobase 
cyclized modifications adopt an anti or anti-like orientation. Free rotation of the 
nucleobase over the glycosidic bond is restricted, which results in an entropy change of 
duplex formation rising from normal nucleotide sequences.  
A wide range of cyclized nucleosides have been proposed and synthesized. Fig. 
1.18 shows some examples of the modifications.  
 
Figure 1.18 A number of linkages between the heterocyclic nucleobase and the 
carbohydrate sugar moiety are reported. Many of the linkages limit the mobility of both 
the sugar moiety and glycosidic bond rotation. 
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1.41 (Fig. 1.18) results from an oxygen linkage between the C2’ and the C6 of the 
nucleobase. These types of modifications have been synthesized by researchers as 
intermediate compounds in the preparation of nucleoside anticancer or antivirus 
prodrugs.151, 152  By connecting to different positions of the sugar and elongating the 
linkage, compounds 1.49 and 1.50 were achieved, 153 and Honjo claimed these 
modifications were able to be used to examine the relationship between the circular 
dichroism (CD) spectra and the sugar-base glycosyl conformation.154 Compounds 1.52 
and 1.53 were synthesized by connecting the C5’ to the nucleobase.155 These 
modifications locked the rotation of the nucleobase and forced it to adopt a conformation 
which would mimic duplex base conformations. Meanwhile two free hydroxyls provided 
the ability to incorporate these compounds into DNA/ RNA double strands, or to form a 
new type of modified nucleic acid. Compound 1.51 was not well studied, but researchers 
believed that this unique class of modified nucleosides could be used as a tool for 
investigating steric interactions between nucleosides or nucleotides and the enzymes that 
utilize them. 155 Modifications 1.55, 1.56, and 1.57, could be classified into one unique 
type of carbon linkage modification, which retained the 3’ and 5’ hydroxyl. These 
modified compounds are more easily incorporated into nucleic acid oligomers in a 
normal 5’ to 3’-linkage. These modifications have been synthesized and characterized, 156, 
157
 and successfully incorporated into oligonucleotides. Their ability to bind with RNA 
and DNA have been investigated. 149, 150 
 
 
 
36 
 
1.7 Applications of modified nucleic acids 
Since nucleic acids were first discovered, they have been extensively studied 
due to their ability to carry genetic information and also as a transportation media.4 
Nucleic acid modifications have been shown to change the properties of nucleic acids. 
This field of research has provided a tool for manipulating nucleic acid behavior for the 
purposes of research and treatment.  Modified nucleic acids have been utilized widely in 
many challenging and popular areas such as antitumor research and treatment81,158,161 and 
antisense technology (RNAi)170-173, 177 among many other fields.189,190  
1.7.1 Modified nucleosides as anticancer and antivirus agents. 
Use of modified nucleosides as anticancer compounds has been extensively 
reported. By the end of 2004, of the sixty small molecule anticancer agents for cancer 
treatment approved by U.S. FDA, 11 of those were nucleosides or derivatives, affecting 
DNA synthesis in a variety of ways.158 Several nucleoside analog drugs, which were 
developed as cancer treatments, are shown below (Fig. 1.19). They are cladribine, 
clofarabine, fludarabine, cytarabine, decitabine, floxuridine, and gemcitabine. Among 
them cladribine, clofarabine, and fludarabine are purine analogs, others are pyrimidine 
analogs. Although they are all nucleoside analogues which are slightly different from 
normal nucleosides, they all function by inhibiting cancer growth in a variety of ways. 
Some of them, such as cladribine, inhibit adenosine deaminase, and interfere with the 
cell's ability to process DNA. Some, such as gemcitabine, are able to induce cell 
apoptosis, while decitabine functions as a potent inhibitor of methyltransferases. 159-164 
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Figure 1.19 Some examples of nucleoside analogue drugs used as anticancer agents. 
Human immunodeficiency virus (HIV) is a very dangous virus and cause 
acquired immunodeficiency syndrome (AIDS) . One primary target for the treatment of 
HIV infection is HIV reverse transcriptase.165 A class of modified nucleosides have been 
introduced for treatment and have shown great activity. The active antiretroviral form of 
the nucleoside analog is a triphosphate anabolite. The modified nucleoside analogs enter 
the same pathway as native nucleosides, triphosphates are installed by cellular kinases. 
Once incorporated, however, the lack of a 3’ hydroxyl caused chain termination during 
the elongation of viral DNA.  
The main problem with the use of these modified nucleosides as anticancer 
and antivirus compounds are their relatively high toxicity,158,166 so efforts continue to find 
compounds with low toxicity and high activity against targets of interest. 
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1.7.2 Modified nucleic acids used in antisense RNAi 
Antisense therapy has proven to be a powerful and efficient tool for genetic 
disorders and infection treatment and research. When a specific genetic sequence of a 
gene is known to be causative of a particular disease or malfunction, antisense therapy 
provides a strategy of treatment where exogenetic nucleic acids (DNA, RNA or other 
modified nucleic acid) are introduced to bind to the messenger RNA produced by that 
gene and inactivate it. Although native DNA and RNA oligonucleotides have been 
reported to demonstrate antisense activity in vitro, much research has been devoted to the 
application of modified oligonucleotides for antisense therapy.167 The primary goals of 
introducing modified nucleic acids were to improve biostability and cellular uptake of the 
oligonucleotides and to optimize tissue and cell distribution for a particular target. 104  
Phosphorothioates and methyl phosphonates were introduced for the purpose of 
reducing enzymatic digestion and facilitating the transportation through the cell 
membrane.168-170 Methyl phosphonates have no charge in their backbone; thereby 
possessing a higher affinity to cross the cell membrane than normal nucleic acids. This 
could be an important factor for gene transferring, but cell membranes could also bind to 
the methyl phosphonate causing loss of the dosage. The introduction of phosphorothioate 
linkages into oligonucleotides enhances their nuclease resistance. 171 However, this 
modification still suffers from a high affinity of sulfur atoms and certain proteins.172 2’-
alkyl modifications of the ribose has also been studied. This modification is less toxic and 
could slightly enhance the binding affinity to its complimentary RNA.173  Recently, 
conformational restriction has been used to enhance binding affinity and biostability. 2-
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Deoxy-2’-fluoro-β-D-arabino nucleic acid (FANA), and locked nucleic acid (LNA) are 
two good examples of this class of molecule. The conformationally restricted nucleic 
acids have shown significantly higher affinity and strong resistance to enzymatic 
digestion.174-176 
RNAi is a system in living cells that helps to control which genes are active and 
how active they are. The mediators of RNAi are two classes of small RNAs including 
microRNA (miRNA) and small interfering RNA (siRNA). RNAi mechanism involves 
short duplex RNAs which are introduced instead of single stranded RNAs in the 
antisense mechanism. Duplex RNA along with enzymes form the RNA induced silencing 
complex (RISC), which serves as a catalyst in gene knockout. Although the short double-
stranded RNA has been successful in silencing in cell culture, researchers are still aware 
of important reasons for the utilization of modified nucleic acids for one or both of the 
strands.177,178 First, enhancement of thermo-stability and nuclease resistance are always 
important for therapeutic purposes. With those properties improved the half-life of the 
siRNA duplexes would increase in vivo. Chemical modifications are able to contribute to 
the improvement of the biodistribution and pharmacokinetic properties of siRNAs and 
help with the specificity of siRNAs to certain cell types. Lastly, one can envision 
improving the potency of siRNA with appropriate chemical modifications which would 
enable the manipulation of siRNA properties including target binding affinity, 
conformation of the modified compounds, A-helix geometry, on-rates and off-rates of 
hybridization, and product release. 179 Many labs have shown that modifications applied 
in antisense therapy can also be applied in the RNAi mechanism.180-183  Examples of 
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phosphorothioates, 2’-sugar modifications, LNA, and Nucleobase modifications have 
been shown to improve RNAi.184-188  
Therefore, sugar conformational restricted modification have been regonized as 
an effective method to alter nucleoside stability with promising biochemical applications. 
However, one step further, another valuable and maybe more powerful approach is 
introduced in this thesis to manipulate nucleoside conformation and properties: base 
conformational restricted modification. This is achieved by setting up a second linkage 
between sugar and base moiety. Such novel modified nucleosides are expected to present 
reduced flexibility and conformational rotation, so they can potentially gain some useful 
properties and characteristics which are not normally observed in native duplexes for 
advanced biochemical applications. 
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2.1 Introduction 
Conformationally restricted nucleosides have been extensively investigated and a 
variety of successful examples have been published.1-3 Most of these modifications were 
achieved through synthetic chemistry, which leads to products not observed in native cell 
metabolism.  
A significant amount of research has revealed that free radicals are produced in 
living cells by normal metabolic processes.4 Of particular interest is the highly reactive 
hydroxyl radical which is able to cause oxidative damage to DNA by abstraction of 
hydrogen atoms from the sugar moieties and subsequent addition to the double bonds of 
the heterocyclic bases.5, 6   Such damage has been implicated in mutagenesis, apoptosis, 
carcinogenesis, and aging.7 From previous research, it has been concluded that hydroxyl 
free radical attack on the sugar moiety of DNA is largely site-specific and occurs 
preferentially at the H(C5’), amounting for more than 50% of this damage.8 The resulting 
lesions result in an intra-molecular linkage between the sugar and nucleobase of the same 
deoxyribonucleoside.  
In this project we focus on 6,5’-cyclo-2’-deoxypyrimidine, which resemble the 
native oxidative damage product of nucleoside, and itscomplimentary partner 8,5’-cyclo-
2’-deoxyadenosine. 8,5’-cyclo-2’-deoxyadenosine is derived from photolytic cleavage of 
coenzyme B12.9 A mechanism for the formation of 8,5’-cyclo-2’-deoxyadenosine is 
shown below (Fig. 2.1). To initiate, the hydroxyl radical abstracts the hydrogen at the C5’ 
position. The resulting free radical then attacks at the C8 of the purine base, leading to 
C8–C5’-cyclization. Subsequent oxidation of the N7-based radical leads to 
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intramolecular cyclization with the formation of a covalent bond between the C5’ and C8 
positions of the purine nucleoside.10 As a consequence, the intra-molecular covalent 
bridge between C5’ to C8 was formed, and the length of the resulting bond has been 
reported to be 1.525 Angstroms,10 which is similar to normal C–C bonds.  Subsequent 
studies have shown that ionizing radiation would be able to cause the formation of 6,5’-
cyclo-2’deoxypyrimidine in DNA in vitro and in vivo through a similar mechanism as 
that discussed for cyclo-2’deoxypurine.11,12  
 
Figure 2.1 Mechanism of 8,5’-cycloadenosine formation through free radical initiation in 
cells. Figure adopted from Zhang and Eriksson.10 
 
Owing to the presence of a covalent bond between the sugar and base moiety of 
the same nucleotide, cyclo-2’-deoxynucleosides are subject to NER (nucleotide-excision 
repair) but not BER (base-excision repair) or other related repair pathways.  
The cyclic 2’-deoxynucleosides were found in native cellular activity. Due to the 
requirement of novel modification, absolute stereo-chemistry, and forming cyclic-cyclic 
nucleoside base pair for further investigation, synthetic preparation of cyclic nucleosides 
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is the preferred method. Both R and S diastereomers of cyclic 2’-deoxypurine are 
synthetically accessible. They cause similar puckering of the sugar and distortion,10 but 
have distinct features, which make them unique and require detailed studies. For example, 
the occurrence of R-diastereomers of cyclic 2’-deoxypurine dominate over the S-
diastereomers in single strand-DNA, whereas the preference is reversed for the S-
diastereomers in double stranded-DNA.14 Moreover, R- and S-diastereomers of cyclic 2’-
deoxypurine might be recognized differently by the repair system due to the possible 
stereo-specificity of the enzymes involved. Subsequent studies confirmed this hypothesis 
and showed that the R-diastereomer is more efficiently repaired than the S-diastereomer. 
15, 16 These differences require diastereomerically pure samples, which can only be 
accessed through synthetic means. 
These cross-linked lesions have major genetic implications, including blocking 
transcription, gene expression inhibition, and transcriptional mutagenesis. Studies have 
proven that the lesions can alter the binding of transcription factors to their cognate DNA 
recognition elements.16 These lesions in TATA cause a transcriptional roadblock, which 
shuts off gene expression as these modifications block TATA Binding Protein (TBP). 
The exact mechanism is not fully understood.17 TBP is known to bind in the minor 
groove thereby causing a major local conformational distortion. One of the reasons that 
nature may have chosen the TATA box instead of a GCGC box is the ease of deformation 
of the minor groove in regions of A•T rather than G•C base-pairs. Since the noted lesions 
block TBP binding, several factors may be operating; either the rigidity imparted by the 
extra covalent bond, or the lesion is resulting in a stronger base-pair in the local duplex, 
or a combination of the two.  Deformation due to the extra bond is definitely playing a 
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role in the inhibition of TBP binding. Whether the lesion makes stronger hydrogen bonds 
with its pair is not clear.  
Our efforts involve the synthesis of stereometrically pure compounds to probe the 
molecular details of these lesions. We designed and synthesized the novel 6,5’-cyclo-2’-
deoxyuridine as the base pair partner of 8,5’-cyclo-2’-deoxyadenosine (Synthesized by 
Han Yueh), in order to investigate duplex properties of these base pairs. The restricted 
flexibility of the sugar -base covalent bond might help to pre-organize and thereby reduce 
entropic loss while forming a base-pair in the DNA duplex. On the other hand, if these 
lesions destabilize the duplex formation, that will confirm that the deformation caused by 
the extra bond make it too rigid, which results in an even weaker base pair than the A•T 
base pair, causing the inhibition of TBP binding.  
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2.2 Preparation of 6,5’-cyclo-2’-deoxyuridine  
Novel compounds 6,5’-cyclo-2’-deoxyuridine (both R and S diastereomers) were 
targets of this synthesis. In this synthesis, a second linkage between the sugar and the 
nucleobase was introduced to rigidify the nucleosides. This modification would lock the 
rotation of the nucleobase over the C1’-N1 glycosidic bond, making the glycosidic angle 
preorganized, similar to those observed in A-form double-stranded nucleic acids. 
Molecular modeling confirmed this hypothesis.  
 
2.2.1 Design of synthetic pathway 
To meet the goal of automated oligonucleotide synthesis, the phosphoramidate of 
6,5’-cyclo-2’-deoxyuridine (Compound 2.13)was the target of this synthesis. In our 
design, the 5’-hydroxyl of the 6,5’-cyclo-2’-deoxyuridine would be installed by Sharpless 
oxidation18 of cyclized compound 2.8. The bridging C-C bond of the cyclo-nucleoside 
was formed via radical mechanism. This implied that the 5’ free radical had an 
inclination to attack the C6 position. To perform a radical cyclization, an iodide group 
was installed at the 5’ of sugar (compound 2.6). The iodide could be achieved by a 
nucleophilic substitution on a good leaving group. From previous experience, the tosyl 
group was chosen as a good leaving group for the nucleoside chemistry. (Scheme 2.1) 
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Scheme 2.1 Retro synthetic analysis of 6,5’-cyclo-2’-deoxyuridine phosphoramidate.  
The chloro at base 5-position was preferred, since the product of cyclization was 
non-aromatic. Subsequent elimination of the chloride on the nucleobase would be able to 
recover the aromaticity. The 5’ tosyl protection was achieved by selective tosylation at 
the primary 5’-hydroxyl group.  
 
 
2.2.2 Synthesis of 6,5’-cyclo-2’-deoxyuridine (Scheme 2.2) 
 The synthesis started from 2'-deoxyuridine. Diacetylation and regio-selective 
chlorination converted the starting material, 2'-deoxyuridine, into 5-chloro-3’,5’-
diacetyldeoxyuridine (compound 2.2). The 5-chloro group was installed to facilitate the 
recovery of aromaticity after 6,5’-cyclization. After deacetylation, selective tosylation at 
the 5’ hydroxyl (compound 2.5) made this position vulnerable to iodination. The 
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following iodide substitution gave compound 2.6, which was available for free radical 
cyclization. Removal of the 5-chloride restored aromaticity to give compound 2.8, and 3’ 
silylation was achieved following an established protocol to give compound 2.9.19 The 
6,5'-cyclo-2',5'-dideoxyuridine was converted to the 5'-hydroxylated derivative 
compound 2.10S, 2.10R using 0.5 eq. SeO2 and 1.5 eq. tBuOOH.(scheme 2.3)  Column 
chromatography of the racemic mixture gave an overall yield of 80%, and the two 
diastereomers 2.10S and 2.10R were produced in a 1:1 ratio.  These two diastereomers 
could be separated by flash column chromatography with triethylamine added in eluent.  
The crystal structure of the fully deprotected compound 2.10S was obtained, and is 
shown in Fig. 2.2. We had difficulty protecting the 5'-hydroxyl of both the R and S 
diastereomers with DMTrCl due to the steric-bulk of both the DMTr protecting group 
and 6,5'-cyclo-2'-deoxyuridine. Therefore, we used ethyl vinyl ether (EVE), which is also 
an acid labile protecting group and could be successfully removed during automated 
oligonucleotide synthesis.  The EVE protected alcohol of each diastereomer resulted in 
compound 2.11S and 2.11R, which co-migrated during silica gel chromatography.  The 
final steps involved removal of the 3'-O-silyl protecting group and conversion to the 
nucleoside 3’-phosphoramidtes (2.13S and 2.13R).  The presence of the two phosphorus 
diastereomers and the two EVE diastereomers could be confirmed by the presence of four 
phosphorus resonances in the final R and S products (e.g., for 2.13R, δ 149.85, 149.48 
149.18, 148.97 ppm). (Scheme 2.2, 2.3) 
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Scheme 2.2 Synthetic route to 6,5’-cyclo-2’-deoxyuridine (1). Reaction conditions:  
i. Ac2O/ pyridine, rt. 4h, 94.8%; ii. CAN/LiCl/acetic acid :acetonitrile (1:1), 80oC, 15h, 
91.9%; iii. 7N ammonia in methanol/ MeOH, rt. 6h, 93.2%; iv. TsCl/pyridine, 0oC to rt. 
12h, 62.0%; v. Ac2O/ pyridine, rt. 12h, 93.9%; vi. NaI/acetone, 56oC, 6h, 86.9%; vii. 
Bu3SnH/AIBN/benzene, 80oC, slowly adding over 4h, then keep reflux 1h, 45.9%; viii. 
NaOEt(2.7M)/EtOH, 78oC, 1h, 90.1%; ix. TIPSCl/1H-imidazole /AgNO3/DIPEA/ 
pyridine, 60oC, 14h, 77.2%. 
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Scheme 2.3Synthetic route of 6,5’-cyclo-2’-deoxyuridine (2). Reaction conditions:  
i. SeO2/tBuOOH/dioxane, 80oC. 3.5h, 41.4% for compound 2.10R, 39.8% for 
compound 2.10S; ii. PPTS/DCM:EVE (2:1), rt. 4h, 79.5% for compound 2.11R, 83.1% 
for compound 2.11S; iii. TBAF/ THF, rt. 1h, 96.5% for compound 2.12R, 97.6% for 
compound 2.12S; iv. N,N,N',N'-tetraisopropyl phosphorodiamidite /tetrazole/acetonitrile,  
rt.6h, 63.4% for  compound 2.13R, 60.2% for compound 2.13S. 
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Figure 2.2 Crystal structure of fully deprotected (S)- 6,5’-cyclo-2’-deoxyuridine. (Crystal 
structure was resolved by Dr. Bo Li) 
2.3 Results and discussion of DNA incorporation 
and Tm study 
The four fused nucleosides, R and S diastereomers for 6,5’-cyclo-2’-deoxyuridine, 
and their complimentary R and S for 8,5’-cyclo-2’-adenosine (Synthesized by Han Yueh 
from our group)were obtained through synthetic means and characterized. Sequences of 
12-mers and 14-mers containing d(AAAA)/d(TTTT) base pairing in the center were 
designed.  Modified cyclo-nucleosides (both modified dU and modified dA) were able to 
be incorporated in these sequences. Each oligonucleotide could be synthesized in 
adequate scale, and the coupling yields for the fused nucleosides were found to be in the 
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90-95% range.  The presence of the cyclo-modification dN derivative could be confirmed 
by established enzyme digestion analysis.21  
Gel shift assays showed that sequences containing modified nucleosides formed 
duplexes with their native complimentary sequences (Fig. 2.3). Ralative higher 
electrophoretic mobility of entry 10 and 11 indicated that sequences containing 6,5’-
cyclo-2’-deoxyuridine would form duplexes looser than native. Circular dichroism (CD) 
studies of those oligonucleotide strands illustrated that modified sequences remained as 
B-form helices (Fig. 2.4). Thermal melting studies of the oligonucleotide strands showed 
destabilization as the fused nucleosides are incorporated. Results did not show any clear 
differences between the strands containing the modified R or the strands with the 
modified S nucleotides.  The thermal melting data is shown below. (Table 2.1) 
Entry Sequence pairs Tm Hypochromi
city 
1 5’-d(C C G G A A A A C G C C)/5’-d(G G C G T T T T C C G G) 49 9.1% 
2 5’-d(C C G G cAS A cAS A C G C C)/5’-d(G G C G T T T T C C G G) 40 6.4% 
3 5’-d(C C G G cAR A cAR A C G C C)/5’-d(G G C G T T T T C C G G) 36 7.1% 
4 5’-d(C C G G A A A A C G C C)/5’-d(G G C G cUS T cUS T C C G 
G) 
28 8.7% 
5 5’-d(C C G G A A A A C G C C)/5’-d(G G C G cUR T cUR T C C G 
G)
 
36 1.5% 
6 5’-d(C C G G A A A A A A C G C C)/5’-d(G G C G T T T T T T C C 
G G) 
51 13.6% 
7 5’-d(C C G G A cAS cAS cAS cAS A C G C C)/5’-d(G G C G T T T T T 
T C C G G) 
17 2.8% 
8 5’-d(C C G G A cAR cAR cAR cAR A C G C C)/5’-d(G G C G T T T T T 28 10.9% 
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T C C G G) 
9 5’-d(C C G G A A A A A A C G C C)/5’-d(G G C G T cUS cUS cUS cUS 
T C C G G) 
28 6.9% 
10 5’-d(C C G G A A A A A A C G C C)/5’-d(G G C G T cUR cUR cUR 
cUR T C C G G) 
16 5.1% 
11 5’-d(C C G G A cAS cAS cAS cAS A C G C C)/5’-d(G G C G T cUS cUS 
cUS cUS T C C G G) 
14 3.0% 
12 5’-d(C C G G A cAS cAS cAS cAS A C G C C)/5’-d(G G C G T cUR cUR 
cUR cUR T C C G G) 
Nd    - 
13 5’-d(C C G G A cAR cAR cAR cAR A C G C C)/5’-d(G G C G T cUS cUS 
cUS cUS T C C G G) 
Nd    - 
14 5’-d(C C G G A cAR cAR cAR cAR A C G C C)/5’-d(G G C G T cUR cUR 
cUR cUR T C C G G) 
Nd    - 
 DNA/RNA hybrid   
15 5’-d(C C G G A A A A C G C C)/5’-G G C G U U U U C C G G 43 4.8% 
16 5’-d(C C G G cAS A cAS A C G C C)/5’-G G C G U U U U C C G G 29 4.1% 
17 5’-d(C C G G cAR A cAR A C G C C)/5’-G G C G U U U U C C G G 30 4.3% 
Table 2.1 Thermal melting data of oligonucleotides with cyclo-nucleosides incorporated. 
cAS and  cAR represent 8,5’-cyclo-2’-deoxyadenosine S and R diastereomers; cUS and  cUR  
respective represent 6,5’-cyclo-2’-deoxyuridine S and R diastereomers. 
 
   1         2          3         4          5        6         7               2        1          8       9         5         10      11  
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Figure 2.3 Gel shift assay showed the duplex formation of sequences containing 
modified nucleosides. 1: 5’-d(G G C G T T T T C C G G); 2: 5’-d(C C G G A A A A C 
G C C); 3: 5’-d(C C G G cAS A cAS A C G C C); 4: 5’-d(C C G G cAR A cAR A C G C C); 
5: 5’-d(G G C G T T T T C C G G)/5’-d(C C G G A A A A C G C C); 6: 5’-d(C C G G 
cAS A cAS A C G C C)/5’-d(G G C G T T T T C C G G); 7: 5’-d(C C G G cAR A cAR A C 
G C C)/5’-d(G G C G T T T T C C G G); 8: 5’-d(G G C G cUS T cUS T C C G G); 9: 5’-
d(G G C G cUR T cUR T C C G G); 10: 5’-d(C C G G A A A A C G C C)/ 5’-d(G G C G 
cUS T cUS T C C G G); 11: 5’-d(C C G G A A A A C G C C)/ 5’-d(G G C G cUR T cUR T 
C C G G); 
 
Figure 2.4 CD experiments of Entries 1-3 (from table 2.1) displayed B-form 
characteristic of duplexes containing modified nucleosides. 1: 5’-d(C C G G A A A A C 
G C C)/5’-d(G G C G T T T T C C G G); 2: 5’-d(C C G G cAS A cAS A C G C C)/5’-d(G 
G C G T T T T C C G G); 3: 5’-d(C C G G cAR A cAR A C G C C)/5’-d(G G C G T T T T 
C C G G). 
80 
 
There are a couple of structural arguments that can explain why these generations 
of cyclo-modified rigid nucleosides do not enhance duplex stability. One would be the 
torsion angles of the duplexes containing cyclo-nucleosides that resemble A-form DNA 
more than B-form. Introducing the bond between C5’ and C6 in 6,5’-cyclo-2’-
deoxyuridine fixed the glycosidic torsion angle χ at  -152.1o.  Whereas, the dA-dT core in 
the Dickerson Dodecamer has χ values ranging from near -80o to near -115o while the 
corresponding RNA sequence exhibits χ values around -160o. These values suggest that 
the fused nucleosides might be better accommodated in a RNA-like A-form duplex. 
However, even the RNA/DNA heteroduplex did not provide additional stabilization 
(entries 15-17, Table 2.1).  
O4'
H(R)O
O(S)
O2
C5'
χ
C4'
γ
γ
 
Figure 2.5: Newman projection along the N1-C1' and C5'-C4' bonds. This figure shows 
that the cyclo-modification would have glycosidic torsion angle χ more similar to A-form 
DNA rather than B-form. 
Another factor would be the presence of the C5'-C6 (modified pyrimidine) or C5'-
C8 (modified purine) bond that limits the distance between the nucleobase and sugar.  
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This bond tends to "pull" the nucleobase towards the sugar backbone, resulting in a 
smaller distance (About a C-C bond) than what is expected for a native nucleoside 
derivative (Fig. 2.6).  This change in position may limit both inter-strand hydrogen bond 
formation between complementary residues, and base stacking efficiency.  
 
Figure 2.6 Overlay of native A-form dU with 6,5’-cyclo-2’-deoxyuridine (left) 
and overlay of native B-form dU with 6,5’-cyclo-2’-deoxyuridine (right) (The overlay 
was done by locking C1’, C3’, and C4’ of both molecules. ) 
The angle for the C4’-C5’ bond (γ) is also problematic.  The γ torsion angle 
prefers a value close to 60o for A-form deoxypyrimidine and a value near 30o for B-form 
deoxypyrimidine.  In these conformations, the projection of the O5’ is in the sugar plane, 
and angled toward the heterocycle (blue arrow in Fig. 2.5).  In the case of the cyclo-
nucleosides, newly formed C5’-C6 bonds forces the projection of the new O5’ out of the 
sugar plane.  The S diastereomer results in a γ torsion angle near -50o while the R 
produces a torsion angle of about -170o (black arrows in Fig. 2.5).   
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2.4 Conclusion 
Our effort towards preparing pure diastereomers of nucleosides of 6,5’-cyclo-
2’deoxyuridine in appreciable yields has been successful. We incorporated these cyclo-
modified nucleosides into DNA sequences and found that the Tm values are reduced. 
These results are in accordance with the theoretical studies done by John Miller.20 Our 
data also establishes that these lesions actually destabilize duplex formation. This 
supports the hypothesis that duplex deformation caused by this lesion overpowers the 
effects of the weaker TATA box base pairing, thus inhibiting TBP binding. The crystal 
structure further explains why these molecules actually form weaker hydrogen bonds as a 
base pair. It is due to the extra bond between the base and the sugar-phosphate backbone, 
which pulls the base away from the position where it can effectively form hydrogen 
bonds. Nevertheless, the fact that the S-diastereomers are resistant towards enzymatic 
repair may contribute to the use of these materials in vivo. 
 
2.5 Experimental 
Reagents were purchased from Sigma-Aldrich, Acros, Oakwood, Glen Research, 
Lancaster, MP Biomedical, Chem-Impex International, Fisher, Chem Genes and 
Molekula. Flash column were performed using Dynamic Adsorbents silica gel (60 Å, 
particle size 32-63 µm) and TLC monitoring with TLC Silica Gel with F-254 Indicator 
(Dynamic Adsorbents). TLCs were visualized by 260nm UV light and stained by 10% 
sulfuric acid. All reactions were carried out under a nitrogen atmosphere with dry solvent 
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under anhydrous conditions unless indicated otherwise. Dry tetrahydrofuran (THF), 
diethyl ether (Et2O), N,N-dimethylformamide (DMF), pyridine (pyr), acetonitrile (ACN), 
and dichloromethane (DCM) were obtained by passing commercially available pre-dried, 
oxygen-free formulations through activated alumina columns. Dry ethanol was purchased 
from Sigma-Aldrich and used directly. NMR spectra were taken as Varian VNMRS400, 
VNMRS500, or INOVA 500 instruments and chemical shifts calibrated using residual 
undeuterated solvent (CDCl3: δ H = 7.24 ppm, δ C = 77.23 ppm, DMSO-d6: δ H = 2.50 
ppm, δ C = 39.51 ppm, Methanol-d4: δ H=3.31 ppm,), and phosphorous 31P NMR was 
calibrated using external standard of 85% H3PO4 in water as 0.0ppm. Abbreviations of 
multiplicities were designated as follow: s = singlet, d = doublet, t = triplet, q = quartet, m 
= multiplet. High-resolution mass spectra (HRMS) were recorded on a Waters LCT or 
JEOL AccuTOF mass spectrometer using ESI (electrospray ionization) or DART (direct 
analysis in real time).  UV spectra were acquired by Beckman (Fullerton, CA) DU650 
spectrophotometer.  HPLC was performed on Waters (Milford, MA) Delta 600 
controllers with a 2487 dual wavelength detector. DNA oligomers were prepared using 
an Applied Biosystems 394 DNA/RNA synthesizer with standard solid phase 
phosphoramidite techniques and reagents purchased from Glenn Research (Sterling, VA). 
RNA oligomers were purchased from Integrated DNA Technologies (Coralville, IA). 
Polyacrylamide Gel Electrophoresis was performed by using a Hoefer Scientific (San 
Francisco, CA) apparatus. Gel imaging was performed on Bio-Rad (Hercules, CA) FXpro 
Molecular Imager with ethidium bromide staining or Kodak-K radioisotope screens. 
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Compound 2.1 
 
Readily available 2’-deoxyuridine (20.2 g, 88.5 mmol), was dissolved in pyridine 
(250 mL) at ambient temperature. After acetic anhydride (20.9 mL, 221.3 mmol) was 
added, the reaction flask was stirred for four hours at ambient temperature. The solvent 
was removed under reduced pressure and the crude product taken up in chloroform (180 
mL) and washed with water (100 mL), and brine (100 mL). After drying over anhydrous 
Na2SO4 and filtration to remove Na2SO4 solid, the organic layer was concentrated in a 
rotary evaporator and purified by flash chromatography (DCM/Acetone 90:10) to yield 
the 3’, 5’-diacetyl-2’-deoxyuridine 6 (26.2 g, 94.8%) as white powder. TLC Rf: 0.49 
(silica gel, DCM/Acetone 90:10); 1H NMR (400 MHz, CDCl3) δ 8.55 (s, 1H), 7.46 (d, J = 
4.8 Hz, 1H), 6.26 (m, 1H), 5.76 (d, J = 8.0 Hz, 1H), 5.19 (t, J = 3.2 Hz, 1H), 4.32 (m, 2H), 
4.25 (m, 1H), 2.52 (m, 1H), 2.14 (m, 1H), 2.10 (s, 3H), 2.09 (s, 3H); 13C NMR (100 MHz, 
CDCl3), δ 170.3, 170.2, 162.7, 150.3, 138.7, 102.9, 85.3, 82.4, 74.0, 63.8, 37.8, 20.9, 20.8. 
HRMS (ESI-TOF) Calc. Mass for [M+H]+ 313.10358, found: 313.10327. 
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Compound 2.2 
 
The 3’, 5’-diacetyl-2’-deoxyuridine (26.2 g, 83.9 mmol) was dissolved in a 1:1 
mixture of acetonitrile and acetic acid (500 mL total). After cerium (IV) ammonium 
nitrate (92.1 g, 168 mmol) and lithium chloride (4.28 g, 101 mmol) were added at 
ambient temperature, the reaction flask was slowly heated to 80 oC and kept stirring for 
15 hours. When TLC monitoring showed the reaction was complete, the solvent was 
removed under reduced pressure. The orange oil-like residue was taken up by ethyl 
acetate (500 mL), and then washed with saturated NaHCO3 (3×200 mL), water (3×200 
mL) and brine (200 mL). The organic layer was dried over anhydrous Na2SO4, and then 
concentrated under reduced pressure and purified by flash chromatography 
(DCM/Acetone 90:10), to yield the 5-chloro-3’, 5’-diacetate-2’-deoxyuridine 2.2 (26.7 g, 
91.9%) as white foam: TLC Rf: 0.34 (DCM/Acetone 90:10). 1H NMR (400 MHz, CDCl3) 
δ 8.86 (s, 1H), 7.78 (s, 1H), 6.28 (t, J = 6.0 Hz 1H), 5.22 (d, J = 4.0 Hz, 1H), 4.39 (m, 2H), 
4.28 (m, 1H), 2.51 (m, 1H), 2.19 (m, 1H), 2.15 (s, 3H), 2.10 (s, 3H); 13C NMR (100 MHz, 
CDCl3), δ 170.6, 170.4, 162.8, 150.2, 139.0, 103.2, 85.5, 82.6, 74.3, 64.0, 38.1, 21.1, 21.0. 
HRMS (ESI) Calc. Mass for [M+H]+: 347.06460, found: 347.06459. 
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Compound 2.3 
 
Compound 2.2 (16.7 g, 48.2 mmol) was dissolved in methanol (150 mL), and 7N 
ammonia in methanol (100 mL) was added at ambient temperature. After stirring at 
ambient temperature for 6 hours, volatiles were removed under reduced pressure, 
resulting brown oil, from which the product was purified by flash chromatography 
(DCM/MeOH 90:10) to yield white powder 8 (11.8 g, 93.2%): Rf=0.33 (DCM/MeOH 
90:10).  1H NMR (400 MHz, DMSO-d6) δ 8.31 (s, 1H), 6.11 (t, J=6.4Hz, 1H), 4.24 (q, 
J=4.4Hz, 1H), 3.79 (q, J=3.2Hz, 1H), 3.60 (qd, J1=12Hz J2=3.2Hz, 2H), 2.11-2.15 (m, 
2H); 13C NMR (100 MHz, DMSO-d6), δ 159.1, 149.6, 137.8, 107.1, 87.6 84.8 70.0, 60.9, 
48.6. HRMS (ESI) Calc. Mass for [M+H]+: 263.04347, found: 263.04429. 
 
Compound 2.4 
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Compound 2.3 (20.0 g, 76.1 mmol) was dissolved in pyridine (600 mL), and then 
cooled to 0 oC. A 4-toluenesulfonyl chloride solution (2.29M in dry pyridine, 45mL, 103 
mmol) was added drop wise via syringe over 1 hour. After addition, the reaction mixture 
was kept at 0 oC for one more hour, and then slowly warmed to ambient temperature and 
stirred over night. The reaction was quenched with water and volatiles were removed 
under reduced pressure, and the brown oil residue was applied to a flash chromatography 
column (DCM/MeOH 90:10) for product purification to yield 9 as white powder (19.6 g, 
62.0%). Rf= 0.65 (DCM/MeOH 90:10).  1H NMR (400 MHz, DMSO-d6) δ 11.87 (s, 1H), 
7.86 (s, 1H), 7.79 (dd, J1=8.4 Hz J2=2.0 Hz, 2H), 6.07 (t, J=6.4 Hz, 1H), 5.43 (d, J=4.4 
Hz, 1H), 4.19-4.27 (m,  2H), 4.15 (m, 1H), 3.88 (m, 1H), 2.41 (s, 3H), 2.18-2.34 (m, 1H), 
2.07-2.11 (m, 1H);13C NMR (100 MHz, DMSO-d6), δ 158.9, 149.4, 145.1, 137.7, 132.1, 
130.1, 127.6, 107.6, 85.0, 83.5, 70.0, 69.7, 38.5, 21.1. HRMS (ESI) Calc. Mass for 
[M+H]+: 417.05232, found: 417.05413. 
 
 
 
 
Compound 2.5 
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Compound 2.4 (7.07 g, 17.0mmol) was dissolved in pyridine (80 mL) at ambient 
temperature. After slowly adding acetic anhydride (4.00 ml, 42.5 mmol), the reaction 
mixture was stirred over night at ambient temperature. The reaction was quenched with 
water, and then solvent was removed under reduced pressure. The resulting brown 
residue was taken up in ethyl acetate (100 mL), and washed with water (50 mL) and brine 
(50 mL). After the volatiles were removed by vacuum, the yellow residue was applied to 
a flash chromatography column (DCM/Acetone 90:10) to purify the product 10 as a 
white powder (7.33 g, 93.9%). Rf=0.42 (DCM/Acetone 90:10).  1H NMR (CDCl3, 400 
MHz) δ 7.81 (d, J = 8.0 Hz, 2H), 7.79 (s, 1H),7.37 (d, J = 8.4 Hz, 2H),  6.29 (q, J = 4.8 
Hz, 1H), 5.21 (d, J=6.8 Hz, 1H), 4.23-4.39 (m, 2H),4.19 (d, J=2.0 Hz, 1H), 2.47-2.49 (m, 
1H), 2.44 (s, 3H), 2.10-2.19 (m, 1H), 2.08 (s, 3H); 13C NMR (CDCl3, 100 MHz), δ 170.7, 
158.4, 149.2, 145.9, 136.3, 132.3, 130.5,  128.2, 110.2, 85.5, 82.8, 74.8, 69.0, 37.7, 21.9, 
21.0. HRMS (ESI) Calc. Mass for [M+H]+: 459.06289, found: 459.06250. 
 
Compound 2.6 
 
A mixture of compound 2.5 (20.0 g, 43.6 mmol) and sodium iodide (13.1 g, 87.2 
mmol) was dissolved in anhydrous acetone (200 mL). The reaction mixture was heated to 
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reflux for 6 hours. After quenching with water, volatiles were removed under reduced 
pressure. The yellow residue was taken up in ethyl acetate (200 mL) and washed with 2 
M sodium thiosulfate (100 mL) and brine (100 mL).  The organic layer was dried over 
anhydrous sodium sulfate, and then concentrated under vacuum to generate a yellow 
foam crude product. The crude material was applied to a flash chromatography column 
(DCM/Acetone 90:10) to yield Compound 2.6 as white foam (15.7 g, 86.9%).  Rf=0.50 
(DCM/Acetone 90:10). 1H NMR (CDCl3, 400 MHz) δ 8.03 (s, 1H), 6.26 (m, 1H), 5.05 (d, 
J = 7.6 Hz, 1H),  3.93 (q, J = 2.8 Hz, 1H), 3.49-3.61 (m, 2H), 2.42-2.48 (m, 1H), 2.23-
2.30 (m, 1H), 2.09 (s, 3H); 13C NMR (CDCl3, 100 MHz), δ 170.7, 158.7, 149.3, 137.0, 
110.1, 85.0, 82.6, 82.5, 37.9, 21.0, 7.7. HRMS (ESI) Calc. Mass for [M+H]+: 414.95577, 
found: 414.95510. 
 
Compound 2.7, 2.8 
 
The 5’-iodo compound 2.6 (11.3 g, 27.3mmol) was dissolved in benzene (600 mL) 
and heated to reflux. A solution of tributyltin hydride (6.9 mL, 26.0 mmol) and 
azobisisobutyronitrile (225 mg, 1.37 mmol) in benzene (50.0 mL) was added drop wise 
over 4 hours. After addition, the reaction mixture was kept at reflux for an extra 45 
90 
 
minutes.  After TLC indicates starting material was fully consumed, the volatiles were 
removed under reduced pressure to yield crude product compound 2.7 as yellow foam.  
The crude product compound 2.7 was directly dissolved in anhydrous ethanol (150 mL), 
and then sodium ethoxide (2.70 M in ethanol) was slowly added.  The reaction mixture 
was heated to reflux and kept refluxing for 1 hour. After cooling to ambient temperature, 
the reaction mixture was neutralized with HCl (1 mol/L aqueous solution).  The 
remaining solvents were removed under vacuum and the product purified by flash 
chromatography (DCM/MeOH 90:10) to yield compound 13 as white powder (3.84 g, 
40.8% over two steps). Rf =0.23 (DCM/MeOH 95:5).  1H NMR (500 MHz, Methanol-d4) 
δ 6.33 (d, J=5.5Hz, 1H), 5.48 (s, 1H), 4.47 (d, J=7.0Hz, 1H), 4.35 (q, J=3.5Hz, 1H), 3.18-
3.23 (m, 1H), 2.72 (d, J=18.5Hz, 1H), 2.51-2.55 (m, 1H), 2.09-2.14 (m, 1H); 13C NMR 
(100 MHz, Methanol-d4), δ 164.3, 150.4, 149.9, 100.1, 83.6, 81.8, 73.2, 44.1, 29.4. 
HRMS (ESI) Calc. Mass for [M+H]+: 211.07188, found: 211.07206. 
 
Compound 2.9 
 
A mixture of compound 2.8 (1.18 g, 5.3 mmol), silver nitrate (1.8 g, 10.6 mmol), 
and imidazole (722 mg, 10.6 mmol) was dissolved in pyridine (50 mL) and N,N-
diisopropylethylamine (1.7 mL, 10.6mmol). The reaction mixture was heated to 60 oC, 
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and triisopropylsilyl chloride (2.25 mL, 10.6 mmol) was added drop wise. The reaction 
mixture was stirring at 60 oC for 14 hours. After TLC indicated the completion, 
ammonium chloride (aqueous solution) was added to quench the reaction. Precipitates 
were filtered out, and filtrates were concentrated under reduced pressure to yield a brown 
oil. The brown oil was taken up by ethyl acetate (100 mL), and washed with saturated 
sodium bicarbonate (75 mL) and brine (75 mL). After the organic layer was separated 
and dried over anhydrous sodium sulfate, volatiles were removed under reduced pressure,    
and the residue was applied to a flash chromatography column (DCM/Acetone 5-10% 
acetone gradient)  to yield compound 14 as white powder (1.50 g, 77.2%).  Rf = 0.21 
(silica gel, DCM/Acetone 95:5); 1H NMR (CDCl3, 400 MHz) δ 8.05 (s, 1H), 6.40 (d, J = 
5.6 Hz, 1H), 5.47 (s, 1H), 4.52 (d, J = 6.4 Hz, 1H), 4.41 (q, J = 3.6 Hz, 1H), 3.21 (ddd, 
J=18, 6.8, 1.8 Hz, 1H), 2.54 (m, 2H), 2.26 (m, 1H), 1.01-1.10 (m, 3H), 1.03 (d, J = 4.8Hz, 
1H); 13C NMR (CDCl3, 100 MHz ) δ 162.1, 149.3, 149.0, 101.5, 84.5, 82.6, 74.9, 46.7, 
30.7, 18.1, 12.1. HRMS (ESI) Calc. Mass for [M+H]+: 367.20531, found: 367.20467. 
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Compound 2.10S, 2.10R 
 
To cyclized product (903 mg, 2.46 mmol) and SeO2 (136 mg, 1.23 mmol) were 
dissolved in 1,4-dioxane (30 mL) and tertbutyl peroxide (480 µL, 3.48 mmol). The 
reaction mixture was heated to 80 oC and stirred for 3.5 hours. When TLC monitoring 
showed that the starting material was fully consumed, the reaction mixture cooled to 
ambient temperature and the insoluble solid was filtered. The filtrate was concentrated 
under reduced pressure to yield a red foam. The residue was purified by flash 
chromatography (DCM/Acetone/Et3N 92:5:3) to yield crude 2.10S and crude 2.10R. 
Separately, each crude diastereomer was further purified by flash chromatography 
(DCM/Acetone 90:10) to yield white powder 2.10R (390 mg, 41.4%), Rf = 0.46 
(DCM/Acetone/Et3N 87:10:3) and white powder 2.10S (375 mg, 39.8%), Rf=0.30 
(DCM/Acetone/Et3N 87:10:3). Compound 2.10S 1H NMR (DMSO-d6, 400 MHz) δ 11.18 
(bs, 1H), 6.49 (d, J=6.4Hz, 1H), 6.18 (d, J=5.2Hz, 1H), 5.65 (s, 1H), 4.71 (q, J=3.6Hz, 
1H), 4.67(t, J=6Hz, 1H), 4.31 (d, J=6Hz, 1H), 2.58 (dd, J1 = 7.6Hz, J2= 16Hz, 1H), 2.00 
(dd, J1=4Hz, J2=8.4Hz, 1H), 1.01-1.08 (m, 3H), 1.03 (d, J=3.2Hz, 18H) ppm; 13C NMR 
(DMSO-d6, 100 MHz ), δ 163.3, 154.6, 149.6, 100.5, 86.3, 84.7, 69.3, 63.2, 45.7, 18.2, 
11.8 ppm; HRMS (ESI-TOF) Calc. Mass for C18H31N2O5Si+ [M+H]+ 383.20022, found: 
383.19989. Compound 2.10R 1H NMR (DMSO-d6, 400 MHz) δ 11.249(bs, 1H), 6.28 (d, 
J=6.4Hz, 1H), 6.22 (d, J=5.2Hz, 1H), 5.62 (s, 1H), 4.46 (dd, J1=3.2Hz, J2=7.2Hz, 1H), 
4.23 (d, J=8.0Hz, 1H), 4.22 (s, 1H), 2.44-2.47 (m, 1H), 1.92-1.98 (m, 1H), 1.05-1.14 (m, 
3H), 1.02 (d, J=6Hz, 1H) ppm; 13C NMR (DMSO-d6, 100 MHz ), δ 163.0, 151.6, 149.4 
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102.7, 89.2, 83.4, 71.1, 64.2, 43.99, 17.7, 11.2 ppm; HRMS (ESI-TOF) Calc. Mass for 
C18H31N2O5Si+ [M+H]+ 383.20022, found: 383.20056. 
  
 
Compound 2.11S, 2.11R 
 
2.10S (138 mg, 0.36 mmol) was dissolved in dry DCM/ethyl vinyl ether (2:1, 
21mL total volume). Pyridinium para-toluenesulfonate (36.4 mg, 0.14 mmol) was added 
and the reaction mixture was stirred at room temperature for 4 hours, resulting in a clear 
solution. Volatiles were removed under reduced pressure and the residue was purified by 
flash chromatography (silica gel pre-washed by three column volumes of DCM/Et3N 99:1 
followed by three column volumes of 100% DCM. Column eluent was DCM/Acetone 
90:10) to yield 2.11S as a white foam (136 mg, 83.1%), Rf=0.33 (DCM/Acetone 90:10). 
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Compound 2.11R was obtained by the same procedure as 2.11S to yield a white foam 
(130 mg, 79.7%), Rf=0.33 (DCM/Acetone 90:10).  Compound 2.11S 1H NMR (CDCl3, 
400 MHz) δ 8.08 (br, 1H), 6.29 (t, J=6Hz, 1H), 6.01 (d, J=1.6Hz, 0.4H), 5.74 (d, J=2.0Hz, 
0.6H), 4.47-4.86 (m, 5H), 3.52-3.62 (m, 2H), 2.45-2.51 (m, 1H), 2.20 (dt, J1=4.4Hz, 
J2=13.2Hz), 1.34-1.38(m, 3H), 1.19-1.23 (m, 3H), 1.03-1.07 (m, 21H) ppm; 13C NMR 
(CDCl3, 100MHz), δ 162.6, 162.5, 152.9, 152.5, 149.0, 147.9, 103.2, 102.1, 101.2, 100.1, 
86.2, 85.7, 85.6, 84.8, 69.7, 69.7, 69.1, 66.7, 62.3, 62.1, 46.5, 46.5, 20.2, 20.2, 18.2, 18.1, 
15.5, 15.5, 12.2, 12.2 ppm; HRMS (ESI-TOF) Calc. Mass for C21H39N2O6Si+ [M+H]+ 
455.25774, found: 455.25732  Compound 2.11R 1H NMR (CDCl3, 400 MHz) δ 8.29 (br, 
1H), 6.36 (t, J=4Hz, 1H), 5.76 (s, 0.4H), 5.69 (s, 0.6H), 4.21-4.99 (m, 5H), 3.47-3.64 (m, 
2H), 2.38-2.50 (m, 1H), 2.17-2.22 (m, 1H), 1.35-1.40 (m, 3H), 1.18-1.23 (m, 3H), 1.07-
1.11 (m, 3H), 1.04 (d, J=3.6Hz, 18H) ppm; 13C NMR (CDCl3, 100MHz ), δ 162.5, 162.5, 
152.9, 149.4, 149.2, 149.1, 148.6, 104.9, 104.5, 99.4, 98.7, 88.2, 86.5, 85.1, 85.0, 71.5, 
71.1, 68.1, 67.7, 60.5, 59.6, 45.4, 45.1, 20.3, 19.8, 18.1, 18.0, 15.4, 15.3, 12.2, 12.1 ppm; 
HRMS (ESI-TOF) Calc. Mass for C21H39N2O6Si+ [M+H]+ 455.25774, found: 455.25664. 
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Compound 2.12S, 2.12R 
 
2.11S (184 mg, 0.41 mmol) was dissolved in THF (4 mL).  TBAF (1 M in THF, 2 
mL) was added and the reaction mixture was stirred at ambient temperature for 45 
minutes. The reaction was quenched with water and the solvents were removed under 
reduced pressure.  The resulting brown oil residue was purified by flash chromatography 
(silica gel pre-washed by three column volumes of DCM/Et3N 99:1 followed by three 
column volumes of 100% DCM. Column eluent was DCM/MeOH 95:5) to afford the 3’ 
OH 5’ S diastereomer 2.11S as a white solid (120 mg, 0.40 mmol), Rf=0.24, 0.20 
(DCM/MeOH 95:5).  The R isomer 2.12R was obtained by the same procedure as a white 
solid in nearly quantitative yield, Rf=0.13 (DCM/MeOH 95:5). Compound 2.12S 1H 
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NMR (DMSO-d6, 400 MHz) δ 11.25 (bs, 1H), 6.14 (d, J=5.2Hz, 1H), 5.64 (s, 0.6H), 5.59 
(s, 0.4H), 5.43 (d, J=5.6Hz, 1H), 5.01 (t, J=4.8Hz, 1H), 4.73 (dd, J1=2.0Hz, J2=24.0Hz, 
1H), 4.43 (m, 2H), 3.61-3.71 (m, 0.8H), 3.51-3.57 (m, 1.2H), 3.01 (bs, 1H), 2.45-2.54 (m, 
1H), 1.95 (dt, J1=4.8Hz, J2=13.6Hz, 1H), 1.30-1.35 (m, 3H), 1.12 (t, J=7.2Hz, 3H) ppm; 
13C NMR (DMSO-d6, 100 MHz) δ 162.7, 151.7, 151.6, 149.1, 101.5, 100.5, 100.4, 99.5, 
84.4, 84.3, 83.7, 68.7, 67.1, 66.9, 66.2, 61.6, 60.0, 44.4, 44.2, 20.3, 19.8, 15.2, 13.5 ppm. 
Compound 2.12R 1H NMR (Methanol-d4, 400 MHz) δ 6.30 (d, J=5.6Hz, 1H), 5.70-5.78 
(m, 1H), 5.01 (q, J=5.2Hz, 1H), 4.38-4.56 (m, 2H), 4.35, (m, 1H), 3.67-3.73 (m, 1H), 
3.57-3.62 (m, 1H), 2.42-2.48 (m, 1H), 2.03-2.09 (dt, J1=4.0Hz, J2=17.6Hz, 1H), 1.37 (m, 
3H), 1.21-1.26 (m, 3H) ppm; 13C NMR (DMSO-d6, 100 MHz) δ 166.0, 165.9, 151.9, 
151.5, 151.3, 104.8, 104.6, 102.3, 100.9, 89.2, 87.9, 85.8, 85.7, 71.3, 71.2, 71.1, 70.8, 
69.6, 62.5, 61.9, 44.3, 44.2, 20.7, 20.4, 15.7 ppm. The S and R diastereomers have similar 
mass spectrometry results.  HRMS (ESI-TOF) for the S compound: Calc. Mass for 
C13H19N2O6+ [M+H]+ 299.12431, found: 299.12320. HRMS (ESI-TOF) for the R 
compound Calc. Mass for C13H19N2O6+ [M+H]+ 299.12431, found: 299.12434. Because 
ethyl vinyl protecting group has one chiral center, two diastereomers of protecting 
product were obtained. To confirm the fact that the mixture styles of compound 2.12S 
and compound 2.12R is caused by chiral center in ethyl vinyl protecting group, we used 
compound 2.12S as an example to separate two new diastereomers. The two 
diastereomers of compound 2.12S were separated by preparative TLC (UniplateTM by 
Analtech Inc.). The faster moving diastereomer of compound 2.12S: 1H NMR (DMSO-d6, 
400 MHz) δ 11.25 (bs, 1H), 6.14 (d, J=5.2Hz, 1H), 5.58 (s, 1H), 5.41 (d, J=5.6Hz, 1H), 
5.00 (dt, J1=5.2Hz, J2=5.2Hz, 1H), 4.70 (dd, J1=1.2Hz, J2=6.2Hz, 1H), 4.44 (m, 2H), 
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3.50-3.65 (m, 2H), 2.45-2.54 (m, 1H), 1.95 (dt, J1=4.8Hz, J2=13.6Hz, 1H), 1.33 (d, 
J=5.2Hz, 3H), 1.14 (t, J=7.2Hz, 3H) ppm; 13C NMR (DMSO-d6, 100 MHz ), δ 162.7, 
151.7, 149.1, 101.6, 100.4, 84.4, 84.3, 68.7, 67.1, 60.0, 44.5, 20.0, 15.2 ppm. The slower 
moving diastereomer of compound 2.12S: 1H NMR (DMSO-d6, 400MHz) δ 11.25 (bs, 
1H), 6.14 (d, J=5.2Hz, 1H), 5.63 (d, J=1.6Hz, 1H), 5.42 (d, J=4.8Hz, 1H), 5.01 (dt, 
J1=J2=4.8Hz), 4.76 (dd, J1=1.6Hz, J2=6Hz, 1H), 4.43 (m, 2H), 3.51-3.73 (m, 2H), 2.45-
2.54 (m, 1H), 1.94 (dt, J1=4.4Hz, J2=13.2Hz, 1H), 1.32 (d, J=5.6Hz, 3H), 1.14 (t, 
J=7.2Hz, 3H) ppm; 13C NMR (DMSO-d6, 100MHz ), δ 162.7, 151.7, 149.1, 100.5, 99.5, 
84.4, 83.7, 67.0, 66.3, 61.7, 44.2, 20.3, 15.2 ppm.  
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Compound 2.13S, 2.13R 
 
The 3’ OH 5’ S diastereomer (184mg, 0.62mmol) was coevaporated with 
acetonitrile (5mL) 3 times, and dissolved in acetonitrile (6.5mL). The stirring reaction 
mixture was cooled to 0 oC and 2-Cyanoethyl N,N,N',N'-tetraisopropyl 
phosphorodiamidite (245 µL, 0.74 mmol), was added followed by tetrazole (0.45 M in 
THF, 830 µL, 0.37 mmol).  The reaction was allowed to warm at ambient temperature 
and stirred for 6 hours before the solvent was removed under reduced pressure. The crude 
residue was subjected to flash chromatography (silica gel pre-washed by three column 
volumes of Hexanes/Et3N 99:1 followed by three column volumes of 100% Hexanes. 
Column eluent was Ethyl Acetate/Hexane 60:40).  This crude material dissolved in dry 
DCM and precipitated from solution upon slow addition of hexanes to yield 2.13S as a 
white foam (185.5 mg, 60.2%), Rf=0.51 (Ethyl Acetate/Hexanes 75:25). Compound 
2.13R was obtained by the same procedure and isolated as a white foam Rf=0.49 (Ethyl 
Acetate/Hexanes 75:25). Compound 2.13S 31P NMR (CDCl3, 200MHz) δ 146.5, 146.5, 
146.2; HRMS (ESI-TOF) Calc. Mass for C22H36N4O7P+ [M+H]+ 499.23216, found: 
499.23142. Compound 2.13R 31P NMR (CDCl3, 200MHz) δ 149.9, 149.5 149.2, 149.0; 
HRMS (ESI-TOF) Calc. Mass for C22H36N4O7P+ [M+H]+ 499.23216, found: 499.23101. 
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1H NMR of Compound 2.1 
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13C NMR of Compound 2.1 
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1H NMR of Compound 2.2 
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13C NMR of Compound 2.2 
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1H NMR of Compound 2.3 
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13C NMR of Compound 2.3 
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1H NMR of Compound 2.4 
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13C NNMR of Compound 2.4 
 
 
107 
 
1H NMR of Compound 2.5 
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13C NMR of Compound 2.5 
 
 
109 
 
1H NMR of Compound 2.6 
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13C NMR of Compound 2.6 
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1H NMR of Compound 2.8 
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13C NMR of Compound 2.8 
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1H NMR of Compound 2.9 
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13C NMR of Compound 2.9 
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1H NMR of Compound 2.10S 
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13C NMR of Compound 2.10S 
 
 
117 
 
1H NMR of Compound 2.10R 
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13C NMR of Compound 2.10R 
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1H NMR of Compound 2.11S 
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13C NMR of Compound 2.11S 
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1H NMR of Compound 2.11R 
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13C NMR of Compound 2.11R 
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1H NMR of Compound 2.12S 
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13C NMR of Compound 2.12S 
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1H NMR of Compound 2.12S-up 
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13C NMR of Compound 2.12S-up 
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1H NMR of Compound 2.12S-down 
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13C NMR of Compound 2.12S-down 
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1H NMR of Compound 2.12R 
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13C NMR of Compound 2.12R 
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31P NMR of Compound 2.13S 
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31P NMR of Compound 2.13R 
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Enzymatic Digestion 
A mixture of 3 µL of alkaline phosphatase, 3 µL of phosphodiesterase I, 4 µL of 
nuclease P1, 10 µL of 10X alkaline phoaphatase buffer, 10 µL of 1.0 M MgCl2, and 70 
µL of water was added to a eppendorf tube containing 2 nmoles of the DNA oligomer. 
The mixture was left at 37 oC overnight, then cooled to room temperature. The digested 
nucleoside mixture was analyzed by reverse-phase analytical HPLC  with a self-packed 
C18 column [0.46 cm 25 cm, 5 µm 100 Å, resins from Varian Analytical Instrument 
(Walnut Creek, CA)]. Mobile phase buffer A: 100 mM triethylammonium acetate buffer 
(pH 7.0). Mobile phase buffer B: acetonitrile. Flow rate: 1 mL/min. Gradient of the 
elution: 0-25% in 30 min and 25-100% in 10 min. The mixtures were monitored by UV 
at 260 nm. 
 
Thermal Denaturation Studies 
All UV melting experiments were carried out in 20 mM pH 7.0 sodium phosphate 
buffer with 100 mM or 1 M sodium chloride using AVIV Biomedical Inc. (Lakewood, 
NJ) spectrophotometer model 14DS UV-Vis with a temperature controller.  Self-
complimentary sequence had a concentration of 1 µM while non-self-complementary 
sequences had concentrations of 0.5 µM for each strand. The samples were heated to 95 
oC for 5 minutes, cooled to room temperature briefly, then further cooled to 4 oC.  
Samples were placed in a 1 cm path length quartz cell with a stopper. The denaturation 
experiments were carried out between 4 oC and 95 oC. Absorption data was collected 
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every degree at 260 nm. The Tm values were determined by the first derivative of the 
melting profile using Origin and Microsoft Excel software. 
 
Circular Dichroism Studies 
All Circular Dichroism experiments were carried out in 20 mM sodium phosphate 
buffer at pH 7.0 with 100 mM or 1 M sodium chloride using AVIV Biomedical Inc. 
(Lakewood, NJ) Circular Dichroism spectrophotometer model 420 with a temperature 
controller. Self-complementary sequence had a concentration of 8 µM while non-self-
complimentary sequences had concentrations of 4 µM for each strand. Samples were 
place in a 1 cm path length quartz cell with a stopper and the denaturation experiments 
were performed at 25 oC. 
 
Circular Dichroism Titration Experiment 
Circular Dichroism titration experiments were carried out in 20 mM sodium 
phosphate buffer at pH 7.0 with 100 mM or 1 M sodium chloride using AVIV 
Biomedical Inc. (Lakewood, NJ) Circular Dichroism spectrophotometer model 420 with 
a temperature controller. The experiment started with 1 mL of 4 µM single-stranded 
DNA solution then adding 1 nmole of complimentary sequence for each titrate point up 
to 4 nmole. 
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Chapter 3 
6,5’-cyclo-6’-hydroxyl-2’,5’-
dideoxyuridine synthesis and 
evaluation 
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3.1 Introduction 
Studies have shown that native nucleosides are very susceptible to oxidation at the 
C5’-position to yield cyclo nucleosides.1,2 To investigate properties of this oxidation 
product, we have previously synthesized 6,5’-cyclo-2’-deoxyuridine. From the results of 
last chapter, we found that the extra bridge bond (6,5’ carbon-carbon bond) pulls the 
nucleobase out of its native position in the modified nucleoside, which resulted in the 
destabilization of the oligonucleotides. Meanwhile, steric hindrance of the newly formed 
5’-hydroxyl of 6,5’-cyclo-2’-deoxyuridine decreased the reactivity of this group towards 
bulky protecting groups. In order to make the modified nucleobase more effectively pair 
with its base-pair partner, a new compound with a longer secondary carbon bridge is 
desired. With this in mind, we developed 6,5’-cyclo-6’-hydroxyl-2’,5’-dideoxyuridine 
(abbr. 6’-hydroxyl cyclo-dU) as a candidate (Fig 3.1). The new design has an extra 
carbon atom in the secondary bridge, which should relieve the positional aberration of the 
modified nucleobase compared to a native duplex. Moreover the primary 6’-hydroxyl 
group, while restricted to one side of the molecule by the chirality at C-5’, can adopt a 
variety of conformations because of free rotation about the C-5’,C-6’ bond.(Fig 3.1) This 
situation contrasts with that of the first generation where the 5’-hydroxyl groups are 
secondary and have fixed orientations. Several attempts have been made in pursuing a 
practical route to nucleobases with an extra methylene in between the C5’ and the 
hydroxyl3-5, but a formal synthesis of a 6’-cyclo-deoxyribonucleoside has remained 
elusive.   
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Figure 3.1 A: Overlay of native A-form dU with molecular model of 6,5’-cyclo-6’-
hydroxyl-2’,5’-dideoxyuridine (top left); B: Overlay of native B-form dU with molecular 
model of 6,5’-cyclo-6’-hydroxyl-2’,5’-dideoxyuridine (top right); C: Overlay of 6,5’-
cyclo-2’-deoxyuridine structure with a molecular model of 6,5’-cyclo-6’-hydroxyl-2’,5’-
dideoxyuridine (bottom). The overlay was done by locking O3’, C1’, and O5’ (or 6’) of 
both molecules.  
Fig 3.1 A and B show the overlay of modeled 6’-hydroxyl cyclonucleoside with 
native A form and B form deoxyuridine. From the overlay, we can easily determine that 
the 6’-hydroxyl cyclo dU more closely resembles the native base compared to the 5’-
hydroxyl cyclo nucleoside (Comparing to Fig. 2.4). The 6’-hydroxyl cyclonucleoside 
more closely resembles the A form conformation rather than B form. Fig. 3.1 C could 
A B C 
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explain this phenomenon by showing the comparison of 6’-hydroxyl cyclonucleoside and 
5’-hydroxyl cyclonucleoside: the extra methylene elongates the distance between the base 
and the hydroxyl group, hence “pushing” the base toward the “native” position. This can 
be attributed to the elongation from the extra methylene carbon of the cyclo nucleoside’s 
backbone. Still, the freedom granted by the hydroxymethyl should not be overlooked. 
This improvement would increase the flexibility of the nucleobase, which would grant a 
better chance at occupying the correct position for duplex formation.  
This extra methylene would not only grant higher flexibility, but also offers a 
more accessible hydroxyl group than the 5’-hydroxyl in 6,5’-cyclo-2’-deoxyuridine. 
Zhang and Eriksson’s theoretical calculation showed that the 5’-hydroxyl in the cyclo-
nucleoside was hindered by the surrounding groups.6 Our attempt to protect the 5’-
hydroxyl of 6,5’-cyclo-2’-deoxyuridine with DMTr group met with difficulty, and such a 
result led us to rethink our strategy. Since the terminal 6’-hydroxyl of 6,5’-cyclo-6’-
hydroxyl-2’,5’-dideoxyuridine is a primary hydroxyl extending out of the rigid structure, 
the 6’-hydroxyl would be less hindered than the 5’-hydroxyl of 6,5’-cyclo-2’-
deoxyuridine. Thus, 6,5’-cyclo-6’-hydroxyl-2’,5’-dideoxyuridine would be easier for 
biological enzymes, such as kinases, to approach and bind with. So, it is our hypothesis 
that the 6’-hydroxyl cyclonucleoside is expected to have a better chance to be utilized by 
biological systems.  
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3.2 Synthesis of R and S diastereomers of 6’-
hydroxyl-6,5’-cyclo-2’-deoxyuridine 
Novel compounds 6’-hydroxyl-6,5’-cyclo-2’-deoxyuridine (both R and S 
diastereomers) were the synthetic targets of this chapter. There are two challenges in this 
synthesis, first was the setup of the linkage between the sugar and the nucleobase through 
C5’- C6 carbon- carbon bond; second was the addition of methylene in between C5’ and 
hydroxyl.  
The synthesis started from intermediate compound 2.9 of synthesis in Chapter II. 
The synthetic pathway to get compound 2.9 was shown below (Scheme 3.1) detail was 
described in Chapter II.  
 
Scheme 3.1 Synthetic route to 6,5’-cyclo-2’-deoxyuridine (1). Reaction conditions:  
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i. Ac2O/ pyridine, rt. 4h, 94.8%; ii. CAN/LiCl/acetic acid :acetonitrile (1:1), 80oC, 15h, 
91.9%; iii. 7N ammonia in methanol/ MeOH, rt. 6h, 93.2%; iv. TsCl/pyridine, 0oC to rt. 
12h, 62.0%; v. Ac2O/ pyridine, rt. 12h, 93.9%; vi. NaI/acetone, 56oC, 6h, 86.9%; vii. 
Bu3SnH/AIBN/benzene, 80oC, slowly adding over 4h, then keep reflux 1h, 45.9%; viii. 
NaOEt(2.7M)/EtOH, 78oC, 1h, 90.1%; ix. TIPSCl/1H-imidazole /AgNO3/DIPEA/ 
pyridine, 60oC, 14h, 77.2% 
 
Sharpless oxidation of compound 2.9 was performed as a start, which installed a 
carbonyl at C5’ of the sugar to yield compound 3.1. The 5’-carbonyl compound 3.1 was 
subjected to trimethylsilyldiazomethane to yield the C5’-epoxide compound 3.2. 
(Scheme 3.2) 
 
Scheme 3.2 Synthetic route of 6’-hydroxyl-6,5’-cyclo-2’-deoxyuridine (2). Reaction 
conditions: i. SeO2/dioxane, reflux, 4h, 74.9%; iii. TMSCHN2/MeOH/DCM, 0oC to rt., 
12h, 56.1%. 
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Figure 3.2 The unprotected R-diastereomer, compound 3.4a, and unprotected S-
diastereomer, compound 3.4b.  
 
Epoxide 3.2 was hydrolyzed under Pt/C and 3.5 bar hydrogen to yield a 
diastereomeric mixture of 3’-triisopropylsilyl-6’-hydroxyl-6,5’-cyclo-2’-deoxyuridine 
(Compound 3.3a and 3.3b in scheme 3.3). To facilitate crystallization, TIPS protection 
was removed with TBAF (1M in THF) to yield the diastereomeric mixture of modified 
nucleosides (compound 3.4a and 3.4b in Fig. 3.2). Due to the similarity of compounds 
3.3a and 3.3b column chromatography was unable to resolve the two diastereomers. We 
were able to separate the two diastereomers via HPLC (See experimental for detail), and 
obtain pure samples of both 3.3a and 3.3b, which were characterized by COSY NMR. 
The HPLC separation was not able to provide sufficient amounts for continued synthetic 
efforts, and an S/R mixture was used as the material to perform EVE 6’-hydroxyl 
protection. After removal of the TIPS protection group at the 3’-position, R-diastereomer 
compound 3.6a was able to be purified and identified, whereas the S-diastereomer, 3.6b, 
was not found (this was identified by using HPLC). We carefully examined the reaction 
and found that the loss of 3.6b might be caused by elimination of the EVE protected 
hydroxyl. (Figure 3.2).    
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Figure 3.3 The S-diastereomer, compound 3.6b, dissociated under TBAF treatment. 
 
The final step was the conversion to the nucleoside 3’-phosphoramidites 
(compound 3.7a).  The presence of the two phosphorus diastereomers and the two EVE 
diastereomers could be confirmed by the presence of four phosphorus resonances in the 
final product. 
 
Scheme 3.3 Synthetic route of 6’-hydroxyl-6,5’-cyclo-2’-deoxyuridine (3). Reaction 
conditions:  i. Pt/C, H2 3.5bar, EtOAc/EtOH(1:1), rt, 24h, 81.3% total yield; ii. 
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PPTS/DCM:EVE (2:1), rt. 4h, 76.2% total yield; iii. TBAF/THF, rt, 1h; iv. Separation, 
45.2%; v. N,N,N',N'-tetraisopropyl phosphorodiamidite /tetrazole/acetonitrile,  rt.6h, 
57.4%. 
 
Previous studies showed chirality inversion at the C5’ position of the modified 
nucleoside under basic treatment.3,8,9. The X-ray crystal structure (resolved by Dr. Bo Li) 
of the fully deprotected, modified nucleosides confirmed the absolute sterechemistry of 
the final products. (Shown in Fig. 3.2) The fully deprotected modified nucleosides were 
achieved by TBAF treatment at the mixture of 3.3a and 3.3b. The resulting compounds 
have a free 6’-hydroxyl and 3’-hydroxyl. 6’-unprotected compound 3.4a, b, and no 
decomposition was observed in desillylation of compound 3.3a and 3.3b. ( A in Fig. 3.2). 
This indicated the fact that the 6’-protecting group facilitated the decomposition. 
 
   
                                  A                                                                B 
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Figure 3.2 Crystal structures of the two diastereomers the modified cyclonucleosides. (A: 
R diastereomer; B: S diastereomer) (Crystal structure was resolved by Dr. Bo Li) 
 
 
 
 
 
 
 
 
 
 
 
3.3 Results and discussion 
3.3.1 DNA incorporation  
We utilized our synthetic nucleoside, Compound 3.7a (because compound 3.6b 
got decomposed, we were not able to incorporate the S-diastereomer), to test the 
characteristics of such modified nucleosides in the context of a DNA duplex. 14 mer 
sequences containing a d(AAAAAA)/d(TTTTTT) channel in the middle were designed 
and synthesized. Modified nucleosides were incorporated into these sequences to replace 
the middle two or four deoxythymidines, making 5’-(GGCGTTU*U*TTCCGG)-3’ and 
5’-(GGCGTU*U*U*U*TCCGG)-3’. In standard ammonium hydroxyide deprotection 
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procedure, the (R)-6’-hydroxyl-6,5’-cyclo-2’-deoxyuridine containing sequences 
dissociated. So ultramild synthesis and deprotection procedure (by Glen Research) was 
applied. Each oligonucleotide was synthesized on a 3 nmol scale, and the coupling yields 
for the fused nucleosides were typically found to be more than 90%.  
Gel shift assays (see experimental for detail) showed that even ultramild synthesis 
(processure provided bt Glen Research) would not secure the integrity of sequences. 
Mass spectroscopy (MALDI) analysis of fragments proved the fact that truncation 
happened in ultramild deprotection. Upon the MALDI result and structure analysis we 
proposed a mechanism shown in Fig. 3.3 leading to sequence degradation. First, base 
would take the 5’ acidic proton, and the resulting negatively charged electron pair would 
be stabilized by conjugation with the adjacent enone system. Then the electron 
withdrawing phosphate could have as a divalent anion, resulting in an α,β,γ,δ-unsaturated 
ketone. The key of this mechanism is the acidity of 5’-hydrogen. Vulnerability to basic 
treatment of 5’-H in similar structures have been  shown in a previous study.9 Sasson and 
Otter performed chirality inversion of (R)-6’-hydroxyl-6,5’-cyclo-5’-deoxyadenosine 
under sodium hydroxide treatment.  In our research a similar result was observed. After 
(R)-6’-hydroxyl-6,5’-cyclo-2’,5’-dideoxyuridine was treated with dilute sodium 
hydroxide aqueous solution, (S)-6’-hydroxyl-6,5’-cyclo-2’,5’-dideoxyuridine was 
observed as a major component in the mixture. 
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Figure 3.3 Dissociation mechanisms of modified sequences during ultramild oligomer 
deprotection. 
 
3.3.2 Anti-cancer biological In-vitro test 
About 13% of all human deaths throughout the world were caused by cancer or 
related diseases, which invoked uncontrolled cell growth, metastasis, and invasion.10 The 
most fatal cancers were lung, stomach, liver, colon, breast, and cervinae.10 Although the 
risk of cancer occurrence increases with age and poverty, several carcinogens, including 
ultraviolet and ionizing radiation, components of  tobacco smoke, and infections from 
certain viruses, bacteria or parasites, account for most occurrences of abnormalities of the 
genetic material, which induce cancer.11 Nucleoside analogues were among the first 
oncology drugs ever developed. Successful nucleoside anti-cancer agents have been 
developed, such as cladribine, clofarabine, and capecitqabine.12-15   
We had  collaborators, Dr. Qian Chen and Dr. Yupeng Chen at Brown University, 
and investigated the anti-cancer activity of our novel modified nucleoside 6’-hydroxyl-
6,5’-cyclo-2’-deoxyuridine (compound 3.4a). We conducted a cell growth inhibition 
experiemt. For the cell growth inhibition assays, we tested our fully deprotected R-
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diastereomer of modified nucleoside (As shown in Fig. 3.2 A) against chondrocytes of 
articular cartilage from knee joints of 4-month old pigs (Primary swine chondrocytes) and 
cancer cell line JJ (Chondrosarcoma). Both types of cells were cultured  in Dulbecco's 
modified Eagle's medium (DMEM, Hyclone) /F-12 Ham media supplemented with 10% 
fetal bovine serum (FBS; Hyclone) and 1% penicillin/streptomycin (P/S; Hyclone) under 
standard cell culture conditions, that is, a sterile, 37 oC, humidified, 5% CO2 / 95% air 
environment. The surviving cell numbers were quantified by standard MTT assay 48 
hours after different concentrations of modified nuecleosides were added into the cell 
media.  
The results showed apparent selective inhibition of chondrosarcoma over primary 
swine chondrocytes (As shown in Fig. 3.3).  R-6’-hydroxyl-6,5’-cyclo-2’-deoxyuridine 
inhibited the growth rate of chondrosarcoma by more than 50% at concentrations higher 
than 177 µM, while primary swine chondrocytes was not significantly affected at that 
concentration. Important to note, compared with some previously modified nucleosides,16 
our R-6’-hydroxyl-6,5’-cyclo-2’-deoxyuridine only presented cell growth inhibition at 
high concentrations. Two possible reasons may cause such a consequence: 1) the 
intracellular delivery of our compound may not be effective. Most of the compound did 
not get into cells. 2) Cells did not pick up and incorporate R-6’-hydroxyl-6,5’-cyclo-2’-
deoxyuridine into their native DNA favorably. In other words, this modified nucleoside 
did not have absolute advantage over native nucleosides to be incorporated into cellular 
DNA. In the second condition, normal tissue cells have a slow proliferation and DNA 
replication rate, and those cells may have a better chance to select native nucleosides. 
Hence, the modified nucleoside inposed much less growth inhibition on normal tissue 
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cells than cancer cells.  As shown in Fig 3.3, we observed different inhibition effects 
between normal and cancer cells. Such a result has a great potential for medical 
applications. Since the balance between efficacy and toxicity of a drug is critical, high 
selectivity of our modified nucleoside to inhibit cancer cell growth may greatly limit the 
side-effect on healthy tissue cells. With regards to its relatively high effective doses, we 
can choose additional approaches (for example, modifying the nucleosides with neutral 
phosphate groups) to enhance its efficiency to be uptaken into cells and incorporated in 
DNA.17  Of course, this is  just  preliminary data. Many further characterizations and 
modifications of the cylo-nucleosides are required.        
 
 
A                                                  B 
Figure 3.3 Cell growth inhibition of R-6’-hydroxyl-6,5’-cyclo-2’-deoxyuridine against 
primary swine chondrocytes (A) and chondrosarcoma (B).  
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3.4 Conclusion 
Here we present the first total synthesis of both diastereomers of the novel 6’-
hydroxyl-6,5’-cyclo-2’-deoxyuridine, with structures that prove their absolute 
stereochemistry. The R disastereomer was successfully converted into a phosphoramidite 
and incorporated into oligonucleotide sequences. We were able to demonstrate the basic 
vulnerability of the modified sequences, which prevented further investigation.  This 
novel type of modified compound showed apparent selectivity in inhibiting cancer cell 
growth over corresponding normal cells. These facts supported the involvement of 6’-
hydroxyl-6,5’-cyclo-2’-deoxyuridine in cell growth (especially in cancer cell growth) and 
exhibited a potential to be a safe anti-cancer agent. 
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3.5 Experimental 
 
All reactions were performed in flame dried glassware under an atmosphere of 
nitrogen using dry solvents unless indicates otherwise. Commercial available reagents 
were purchased from Sigma-Aldrich, Acros, Oakwood, Lancaster, Chem-Impex 
International, Fisher, Chem Genes and Molekula. Silicycle silica gel (60 Å, particle size 
40-63 µm) was used for flash chromatography and TLC Silica Gel with F-254 Indicator 
(60 Å, Silicycle) was used for TLC monitoring. TLCs were visualized by 260nm UV 
light and stained by 10% sulfuric acid. Anhydrous tetrahydrofuran (THF), diethyl ether 
(Et2O), N,N-dimethylformamide (DMF), pyridine (pyr), acetonitrile (MeCN), and 
dichloromethane (DCM) were obtained by passing commercially available pre-dried, 
oxygen-free formulations through activated alumina columns. Anhydrous ethanol 
(reagent alcohol) was purchased from Sigma-Aldrich and used directly. Anhydrous 
methanol was purified and dried by standard techniques and distilled prior to use.  NMR 
spectra were taken by Varian VNMRS400, VNMRS500, or INOVA 500 instruments and 
calibrated using residual undeuterated solvent (CDCl3: δ H = 7.24 ppm, δ C = 77.23 ppm, 
DMSO-d6: δ H = 2.50 ppm, δ C = 39.51 ppm, Methanol-d4: δ H=3.31 ppm, δ C = 49.15 
ppm), and phosphorous 31P NMR was calibrated using external standard of 85% H3PO4 
in water as 0.0ppm. Abbreviations of multiplicities were designated as follow: s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet. High-resolution mass spectra (HRMS) 
were recorded on a Waters LCT or JEOL AccuTOF mass spectrometer using ESI 
(electrospray ionization) or DART (direct analysis in real time).  UV spectra were 
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acquired by Beckman (Fullerton, CA) DU650 spectrophotometer.  HPLC was performed 
on Waters (Milford, MA) Delta 600 controllers with a 2487 dual wavelength 
detector. DNA oligomers were prepared using an Applied Biosystems 394 DNA/RNA 
synthesizer with standard solid phase phosphoramidite techniques and reagents purchased 
from Glenn Research (Sterling, VA). Polyacrylamide Gel Electrophoresis was performed 
by using a Hoefer Scientific (San Francisco, CA) apparatus. Gel imaging was performed 
on Bio-Rad (Hercules, CA) FXpro Molecular Imager with ethidium bromide staining or 
Kodak-K radioisotope screens. 
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3.5.1 Synthesis 
The synthesis started at intermediate compound 2.9 from the synthesis in Chapter 
II. The preparation of compound 2.9 in Chapter III was following the same pathway as 
inChapter II. 
 
Compound 3.1 
 
Compound 2.9 (733 mg, 2.00 mmol) and selenium dioxide (333 mg, 3.01 mmol) 
were dissolved in 1, 4-dioxane (25 mL). The reaction mixture was heated to reflux and 
stirred for 4 hours. After TLC indicated the completion of the reaction, the mixture was 
allowed to cool to ambient temperature and insoluble solids were removed by filtration. 
The filtrate was concentrated under reduced pressure to yield red foam. The residue was 
purified by flash chromatography (DCM/acetone 95:5) to yield compound 3.1 as white 
foam (570 mg, 74.9%). Rf = 0.31 (silica gel, DCM/Acetone 95:5); 1H NMR (CDCl3, 400 
MHz) δ 9.47 (s, 1H), 6.54 (d, J = 5.6 Hz, 1H), 6.38 (s, 1H), 4.70 (s, 1H), 4.65 (m, 1H), 
2.57-2.62 (m, 1H), 2.37-2.43 (m, 1H), 1.07-1.10 (m, 3H), 1.04(d, J=2.8Hz, 18H); 13C 
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NMR (CDCl3, 100 MHz ) δ 185.7, 162.5, 148.8, 141.4, 104.2, 90.8, 85.5, 72.7, 44.4, 18.0, 
12.0. HRMS (ESI) Calc. Mass for [M+H]+: 381.18457, found: 381.18530. 
 
Compound 3.2 
 
Compound 3.1 (3.18 g, 8.36 mmol) was dissolved in a mixture of anhydrous 
methanol and anhydrous dichloromethane (DCM/ Methanol 1:1, 320 mL total volume). 
The stirring reaction mixture was cooled to -78 oC, and then added 
trimethylsilyldiazomethane drop wise over 15 minutes. The resulting mixture was kept 
stirring at -78 oC for 1 hour, before being warmed up to -10 oC and stirred for 3 hours. 
Then the reaction mixture was warmed to ambient temperature and stirred over night. 
When TLC had indicated the complete consumption of starting materials, the reaction 
was quenched with saturated ammonium chloride (10 mL).  After solvents were removed 
under reduced pressure, the residue was taken up by dichloromethane (100 mL) and 
washed by water (50 mL) and brine (50 mL). The organic layer was concentrated by 
rotary evaporator and purified by flash chromatography (DCM/Acetone 0-10% Acetone 
gradient) to yield an off-white powder compound 3.11 (1.85 g, 56.1%). Rf = 0.16 (silica 
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gel, DCM/Acetone 95:5);  1H NMR (CDCl3, 400 MHz) δ 8.22 (s, 1H), 6.45 (d, J=5.2Hz, 
1H), 5.48 (s, 1H), 4.75 (q, J=3.6Hz, 1H), 4.02 (s, 1H), 3.19 (d, J=5.2Hz, 1H), 3.08 (d, 
J=5.2Hz, 1H), 2.59-2.64 (m, 1H), 2.28-2.33 (m, 1H), 1.06-1.09 (m, 1H), 1.02 (d, J=6Hz, 
18H). 13C NMR (CDCl3, 100 MHz) δ 162.1, 150.7, 148.9, 98.1, 87.0, 85.9, 72.0, 59.9, 
52.2, 46.2, 18.0, 12.0. HRMS (ESI) Calc. Mass for [M+H]+: 395.20022, found: 
395.19975. 
 
                    
Compounds 3.3a, 3.3b 
 
Compound 3.2 (288 mg, 0.73 mmol) was dissolved in a mixture of dry ethyl 
acetate and dry ethanol (ethyl acetate/ ethanol 1:1, total 50 mL volume), and then 
platinum on activated charcoal (360 mg, 5% Pt) was added. The reaction mixture was 
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kept under hydrogen (3.5 bar, about 50.8 psi) and was shaken at ambient temperature for 
24 hours. After the completion of the reaction, the insoluble solids were filtered and the 
solvents were removed under reduced pressure. The resulting off-white residue was 
purified by flash chromatography to yield a mixture of 3.3a and 3.3b as white powder 
(235 mg, 81.3% total yield). The compounds 3.3a and 3.3b were separated by HPLC (see 
HPLC attachment 1).  For compound 3.3a Rf = 0.29 (silica gel, DCM/Methanol 95:5); 1H 
NMR (CDCl3, 400 MHz) δ 8.09 (s, 1H), 6.38 (d, J=5.6 Hz, 1H), 5.71 (s, 1H), 4.84 (dd, 
J1=6.8 Hz J2=2.8 Hz, 1H), 4.55 (d, J=6.4 Hz, 1H), 3.96 (d, J=5.2Hz, 2H), 3.34-3.35 (m, 
1H), 2.45-2.50 (m, 1H), 2.23-2.27 (m, 1H), 1.06-1.10 (m, 3H), 1.04 (d, J=4.8 Hz, 18H); 
13C NMR (Methanol-d4, 100 MHz) δ 166.1, 154.0, 151.4, 100.8, 87.2, 85.8, 72.4, 60.7, 
47.3, 42.5, 18.6, 13.4. HRMS (ESI) Calc. Mass for [M+H]+: 397.21587, found: 
397.21423. For compound 3.3b Rf = 0.28 (silica gel, DCM/Methanol 95:5); 1H NMR 
(CDCl3, 400 MHz) δ 7.84 (s, 1H), 6.35 (d, J=4.0 Hz, 1H), 5.57 (s, 1H), 4.57 (s, 1H), 4.40 
(m, 1H), 3.81-3.94 (m, 2H), 2.64-2.67 (m, 1H), 2.48-2.52 (m, 1H), 2.21-2.25 (m, 1H), 
1.06-1.11 (m, 3H), 1.04 (d, J=4.8 Hz, 18H); 13C NMR (Methanol-d4, 100 MHz) δ 165.8, 
152.4, 151.4, 103.7, 86.2, 85.2, 76.2, 65.6, 47.5, 45.0, 18.7, 13.5. HRMS (ESI) Calc. 
Mass for [M+H]+: 397.21587, found: 397.21469. 
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Compounds 3.4a, 3.4b 
 
To get X-ray crystallography which will show us the absolute structure of novel 
modified nucleoside. Compound 3.3a (23.5 mg) was dissolved in tetrahydronfuran (1.0 
mL), and slowly added tetrabutylammonium fluoride (1M in THF, 0.5 mL). Reaction was 
stirred at ambience temperature for 1 hour. Volatiles were removed under reduced 
pressure, to yield yellow oil crude product 3.4a. It was further purified by HPLC (see 
HPLC attachment 2).  Following the same procedure 3.4b was obtained and purified. For 
compound 3.4a Rf = 0.15 (silica gel, DCM/Methanol 90:10); 1H NMR (DMSO-d6, 400 
MHz) δ 11.18 (s, 1H), 6.16 (d, J=5.6 Hz, 1H), 5.66 (s, 1H), 5.19 (d, J=4.4 Hz, 1H), 5.08 
(t, J=4.8 Hz, 1H) 4.43 (m, 1H), 4.39 (d, J=6.4 Hz, 1H), 3.63-3.79 (m, 2H), 3.24 (m, 1H), 
161 
 
2.33-2.39 (m, 1H), 1.90-1.96 (m, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 162.8, 151.6, 
149.5, 99.4, 84.3, 83.7, 67.9, 59.2, 44.2, 40.7. HRMS (ESI) Calc. Mass for [M+H]+: 
241.08245, found: 241.08143 . For compound 3.4b Rf = 0.15 (silica gel, DCM/Methanol 
90:10); 1H NMR (DMSO-d6, 500 MHz) δ 11.18 (s, 1H), 6.16 (d, J=5.5 Hz, 1H), 5.49 (s, 
1H), 5.34 (d, J=4.5 Hz, 1H), 5.28 (t, J=5.7 Hz, 1H) 4.44 (s, 1H), 4.23 (m, 1H), 3.33-3.57 
(m, 2H), 2.65 (m, 1H), 2.36-2.43 (m, 1H), 1.92-1.95 (m, 1H); 13C NMR (DMSO-d6, 100 
MHz) δ 162.8, 149.9, 149.6, 102.1, 83.5, 82.5, 72.0, 63.3, 44.3, 42.5. HRMS (ESI) Calc. 
Mass for [M+H]+: 241.08245, found: 241.08206. 
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Compounds 3.5a, 3.5b 
 
A mixture of 3.5a and 3.5b (400 mg, 1.01 mmol) was dissolved in dry DCM/ethyl 
vinyl ether (3:2, 100mL total volume). Pyridinium para-toluenesulfonate (377 mg, 1.00 
mmol) was added and the reaction mixture was stirred at room temperature for 3.5 hours, 
resulting in a yellowish solution. Volatiles were removed under reduced pressure and the 
residue was purified by flash chromatography (silica gel pre-washed by three column 
volumes of DCM/Et3N 99:1 followed by three column volumes of 100% DCM. Column 
eluent was DCM/Acetone 90:10) to yield 3.5a and 3.5b as a white foam mixture (357 mg, 
76.2%), Rf=0.38 (DCM/Acetone 90:10).  Due to inseparability of the two diastereomers, 
NMR was not helpful. Instead, high-resolution mass spectroscopy was done and prove 
the formation of product: HRMS (ESI) Calc. Mass for [M+H]+: 469.27339, found: 
469.27291. 
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Compound 3.6a 
 
Mixture of 3.5a and 3.5b (216 mg, 0.46 mmol) was dissolved in THF (6 mL).  
TBAF (1 M in THF, 3 mL) was added and the reaction mixture was stirred at ambient 
temperature for 1 hour. The reaction was quenched with water and the solvents were 
removed under reduced pressure.  The resulting brown oil residue was purified by flash 
chromatography (silica gel pre-washed by three column volumes of DCM/Et3N 99:1 
followed by three column volumes of 100% DCM. Column eluent was DCM/MeOH 95:5) 
to afford pure 3’-hydroxyl 5’ R diastereomer 3.6a as a white solid (65 mg, 0.21 mmol, 
45.2%), Rf=0.41 (DCM/MeOH 90:10). S diastereomer 3.6b was not found from this 
reaction due to decomposition. Compound 3.6a 1H NMR (DMSO-d6, 400M Hz) δ 11.22 
(bs, 1H), 6.17 (d, J=4.8Hz, 1H), 5.57 (s, 1H), 5.37 (d, 1H), 4.73 (t, J=4.0Hz, 1H), 4.38 (d, 
J=5.2Hz, 1H), 4.25 (m, 1H), 3.42-3.68 (m, 4H), 2.86 (m, 1H), 2.40-2.45 (m, 1H), 1.90-
1.95 (dt, J1=5.2Hz, J2=13.6Hz, 1H), 1.24 (d, J=1.6Hz, 1.7H), 1.22 (d, J=2.0Hz, 1.3H) 
1.19 (t, J=7.2Hz, 1.3H) 1.11(t, J=7.2Hz, 1.7H) ppm; 13C NMR (DMSO-d6, 100M Hz) δ 
163.0, 150.0, 149.9, 149.8, 102.8, 100.0, 99.7, 84.1, 83.3, 83.2, 72.3, 67.1, 61.4, 61.0, 
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46.1, 44.7, 43.9, 20.4, 20.3, 15.7, 15.6 ppm. eHRMS (ESI-TOF) for compound 3.6a: Calc. 
Mass for [M+Na]+ 335.1211, found: 335.1219. 
 
Compound 3.7a 
 
Starting material compound 3.6a (143mg, 0.5mmol) was coevaporated with 
acetonitrile (3 X10mL), and dissolved in acetonitrile (5mL). The stirring reaction mixture 
was cooled to 0 oC and 2-Cyanoethyl N,N,N',N'-tetraisopropyl phosphorodiamidite (165 
µL, 0.71 mmol), was added followed by tetrazole (0.45 M in THF, 560 µL, 0.25 mmol).  
The reaction was allowed to warm at ambient temperature and stirred for 10 hours before 
the solvent was removed under reduced pressure. The crude residue was subjected to 
flash chromatography (silica gel pre-washed by three column volumes of hexanes/Et3N 
99:1 followed by three column volumes of 100% hexanes. Column eluent was ethyl 
acetate/hexane 60:40.  This crude material was dissolved in dry DCM and precipitated 
from solution upon slow addition of hexanes to yield 3.7a as a white foam (147.2 mg, 
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57.4%), Rf=0.45 (ethyl acetate/hexanes 75:25). 31P NMR (CDCl3, 200M Hz) δ 149.6, 
149.4, 149.3, 149.2; HRMS (ESI-TOF) Calc. Mass [M+H]+ 513.24781, found: 513.24843.  
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1H NMR of Compound 3.1 
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13C NMR of Compound 3.1 
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1H NMR of Compound 3.2 
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13C NMR of Compound 3.2 
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1H NMR of Compound 3.3a 
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13C NMR of Compound 3.3a 
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1H NMR of Compound 3.3b 
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13C NMR of Compound 3.3b 
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1H NMR of Compound 3.4a 
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13C NMR of Compound 3.4a 
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1H NMR of Compound 3.4b 
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13C NMR of Compound 3.4b 
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1H NMR of Compound 3.4a 
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13C NMR of Compound 3.6a 
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31P NMR of Compound 3.7a 
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3.5.2 HPLC program  
HPLC attachment 1: HPLC program is running a gradient from 5% acetonitrile in 
water (including 0.1% TFA) to 41% acetonitrile in water (including 0.1% TFA) over 10 
minutes, then from 41% acetonitrile in water (including 0.1% TFA) to 63.5% acetonitrile 
in water (including 0.1% TFA) over 10 minutes, followed by from 63.5% acetonitrile in 
water (including 0.1% TFA) to 95% acetonitrile in water (including 0.1% TFA) over 20 
minutes. 
HPLC attachment 2: HPLC program is running a gradient from water (including 
0.1% TFA) to 12.5% acetonitrile in water (including 0.1% TFA) over 15 minutes, then 
from 12.5% acetonitrile in water (including 0.1% TFA) to 50% acetonitrile in water 
(including 0.1% TFA) over 15 minutes. 
 
3.5.3 Ultramild synthesis and gel shift assay 
The synthesis of labelled oligonucleotides was carried out at the ultramild 
synthesis condition suggested by Glen Research.18 A set of monomers using 
phenoxyacetyl (Pac) protected dA and 4-isopropyl-phenoxyacetyl (iPr-Pac) protected dG, 
along with acetyl protected dC, were designed to meet the desired criteria for Ultramild 
synthesis and deprotection. Beyond the usage of above phosphoramidite, phenoxyacetic 
anhydride (Pac2O) in Cap A was used instead of normal acetic anhydride. This 
modification removes the possibility of exchange of the iPr-Pac protecting group on the 
dG with acetate from the acetic anhydride capping mix. Cleavage and deprotection was 
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carried out in 4 hours with freshly made 0.05M potassium carbonate in methanol. Due to 
the suspection of incomplete deprotection, the synthesis solid beads were preserved and 
conducted an extra 24 hour deprotection using the same deprotection solution. The extra 
deprotection products were labeled “C” after their names. (Figure 3.4) 
 
 
 
Figure 3.4 Denature gel shifts of ultramild synthesis and deproduction products. YHS-
014 and YHS-015 were unmodified sequences; YHS-016 and YHS-017 were modified 
sequences. Mass spectroscopy of every spots were done and shown below.  
 A 
A 
 
 A 
B  
 A 
B 
 A 
C 
 A 
D 
 A 
E 
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 Mass Corresponding sequence Source 
YHS-016 4273.8 5’- d(GGCGTTU*U*TTCCGG) - 3’ Calculated 
YHS-017 4269.8 5’- d(GGCGTU*U*U*U*TCCGG) - 3’ Calculated 
A 1764.13 5’-d(U*1 TCCGG )-3’ MALDI 
B 1600.28 5’-d(GGCGT*2 )-3’ MALDI 
C 2068.34 5’-d(U*1 TTCCGG)-3’ MALDI 
D 1904.30 5’-d(GGCGTT*2)-3’ MALDI 
E 4133.84 NA MALDI 
U*=  U*1= T*2=  
 
3.5.4 Cell culture19  
Swine chondrocytes (isolated from articular cartilage from knee joints of 4-month 
old pigs as described in the previous reference19) and human fetal chondrosarcoma 
(cancer cell line JJ) were cultured in Dulbecco's modified Eagle's medium (DMEM, 
Hyclone) /F-12 Ham media supplemented with 10% fetal bovine serum (FBS; Hyclone) 
and 1% penicillin/streptomycin (P/S; Hyclone) under standard cell culture conditions, 
that is, a sterile, 37 oC, humidified, 5% CO2 / 95% air environment.  
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For cell proliferation studies, chondrocytes and chondrosarcoma cells were seeded 
separately at 5,000 cells/well into polystyrene 96-well plates under standard cell culture 
conditions (37oC, 5% CO2, 95% air humidification) for 24 hours. Then, modified 
nucleoside was added into each well to finial concentrations of 10nM, 50nM, 100nM, 
200nM, and 500nM. After 48 hours, cell densities were determined via a MTT assay 
(Invitrogen). Light absorbance was measured at 570 nm on a Spectra MAX 190 
spectrophotometer (Molecular Devices). Cell density was normalized by the controls (no 
modified nucleoside). 
Statistical analysis: All results were repeated by three times and used ANOVA 
followed by t-test with significance determined at p<0.05. 
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Chapter 4 
2’-deoxy-6,3’-propanouridine and 2’-
deoxy-6,3’-butanouridine synthesis  
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4.1 Introduction 
In recent years, conformationally locked nucleosides have attracted attention as 
therapeutic and diagnostic tools.1-4 These modified nucleosides have helped us to 
understand the influence that conformation has on nucleic acid duplex formation, and 
helped to elucidate the conformational preference of nucleosides in some nucleoside-
enzyme complexes.5 Major efforts have been focused on fixing the conformation of the 
sugar moiety, such as α and β LNA. This research provided evidence of a preference of 
sugar conformation when nucleosides bind to enzymes. While these modifications induce 
tight binding interactions, base conformationally locked modifications have little 
successful examples which are now gaining more and more attention.6  
In previous chapters we discussed two generations of 6,5’-cyclo modifications, 
whose glycosidic torsion angle χ was similar to A-form nucleic acids. The goal of this 
new class of molecules was to mimic native DNA, which commonly adopts a B-form 
helix as its most stable structure. Glycosidic torsion angle χ in nucleic acid is referring to 
the torsion angle between C1’-O4’ bond and N1-C2 bond in pyrimidine (as N9-C4 bond 
in purine). The χ angles of A-form and B-form DNA have nearly a 50o difference (Fig. 
4.1). The glycosidic torsion angle in B-form DNA is usually about -100o, whereas in A-
form is about -160o.7,8   
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B-form deoxythymidine                     A-form deoxyuridine  
Figure 4.1 Glycosidic torsion angles in B-form and A-form nucleosides.  
Ueda and colleagues investigated a new type of cyclo-modification, which 
connected the C3’-position of the sugar moiety and the C6-position of the nucleobase 
through a covalent bond.9,10  This type of modification fixed the glycosidic torsion angle 
to -94.7o, which resembled the B-form structure (Fig 4.2).11 Researchers claimed this 
modification to be a good candidate to mimic B-form nucleosides in DNA for biological 
studies. Studies showed that these compounds could be brought to their corresponding 
phosphoramidites and incorporating into oligomers. In the same publication, thermal 
stability and nuclease resistance of the modified sequences including 6,3’-carbon bridged 
nucleosides were investigated.12 The result indicated that 6,3’-methanodeoxyuridine 
showed resistance at the 5’-phosphodiester linkage against the action of the 3’-
exonuclease, snake venom phosphodiesterase. However, the thermal stability of the 
duplex containing the modified sequences were reduced, the author proposed that the 
position of the nucleobase being abnormal was the main factor for the destabilization.  
O
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Figure 4.2 6,3’-carbon bridged nucleosides synthesized by Ueda et al.11 (Modified 
deoxycytidine at left, modified deoxyuridine at right) 
To overcome this drawback, Freier and colleagues developed 6,3’-
ethanonucleosides, which increase the length of the carbon bridge from one carbon to two 
(Fig. 4.3), expecting a higher affinity toward complementary oligonucleotides.13 This 
modified uridine was predicted to adopt the conformation whose glycosidic torsion angle 
was close to standard B-form DNA. This modification increased the duplex stability 
compared to Ueda’s original version, but still held lower thermal stability than native 
oligonucleotide duplexes. This result indicated that the extra carbon in the bridge would 
help position the nucleobase to fit the requirement for duplex formation, but still not 
place the nucleobase in an ideal position. Another factor for the duplex destabilization of 
the two modifications described was the rigidity of the two structures. Although Freier’s 
version improved the flexibility of the modified nucleosides, apparently this was still not 
enough to satisfy the duplex. However, experimental evidence showed that too much 
conformational flexibility in a modified DNA strand would induce drastic drops in the 
binding affinity of this strand towards the complementary sequences as well.14  
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                              A                                         B 
Figure 4.3 2’-O-methyl-6,3’-ethano-cyclouridine synthesized by Freier et al., and 
molecular modeling of lowest energy conformer of 2’-deoxy-6,3’-ethano-cyclouridine (B 
was obtained from molecular mechanics computations using AMBER all-atoms force 
field.). (Figure was adopted from reference 13) 
 
The ideal modification would need two characteristics: moderate flexibility and 
the appropriate positioning of the nucleobase. Following these principles, we designed 
two new 6,3’-cyclo-modifications including three or four carbon atoms in the bridge. 
This improvement should provide higher flexibility to the structure while the base 
rotation is still limited to fit the requirement of duplex formation. 
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4.2 Preparation 
Novel compounds 2’-deoxy-6,3’-propanouridine and 2’-deoxy-6,3’-butanouridine 
are targets of this synthesis. In this scheme, an extra propano-linkage between the sugar 
3’-carbon and the nucleobase 6-carbon is introduced, and in future butano-linkage will be 
investigated. The resulting compounds will have a restricted glycosidic preorganization 
and moderate flexibility, which is designed to enhance the affinity of the incorporated 
oligonucleotides to their B-form complimentary DNA sequences.  
 
4.2.1  Design of synthetic pathway 
The target of these syntheses are 2’-deoxy-6,3’-propanouridine and 2’-deoxy-
6,3’-butanouridine. In our design, these two compounds can be reached by 
dehydroxylation of two corresponding ribonucleosides. The imidazolylthiocarbonation 
product proved to be a good candidate for these dehydroxylations.15 The 3’-hydroxyl can 
be protected before the thiocarbonation at the 2’-hydroxyl. Considering the potential 
vulnerability of the nucleoside glycosidic bond under the harsh basic conditions required 
for the cross-coupling reaction between the carbon chain and the sugar, all previous 
publications suggested that the carbon chain would be installed before the glycosylation 
reaction at C1’. Our synthesis also followed this strategy. Acetyl protected hemiacetal is 
an ideal substrate for glycosylation, while isopropylidene protection is required for 
previous reactions. So, a switch from isopropylidene to acetyl protection groups is done 
just before the glycosylation. (Shown in Fig. 4.4) 
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Figure 4.4 Retro synthetic scheme of 2’-deoxy-6,3’-propanouridine (A) and 2’-deoxy-
6,3’-butanouridine (B). (1) 
 
The cross coupling is achieved by nucleophilic attack of the nucleobase moiety on 
the corresponding bromide, where the substrate for 2’-deoxy-6,3’-propanouridine has a 
two carbon chain, and the substrate for 2’-deoxy-6,3’-butanouridine has a three carbon 
chain. (See Fig 4.5) The bromide group is installed by treating the corresponding alcohol 
with carbon tetrabromide and triphenylphosphine in both pathways. Alcohols are 
obtained by nucleophilic coupling of corresponding bromide and sugar ketone. 
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Figure 4.5 Retro synthetic scheme of 2’-deoxy-6,3’-propanouridine and 2’-deoxy-6,3’-
butanouridine. (2) 
The ketone on the sugar is achieved by oxidation of the 3’-hydroxide compound, 
and the protected sugar is derived from commercially available D-xylose. The base 
moiety is obtained through chlorination followed by sodium methoxide treatment from 
commercially available thymine.  
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4.2.2 Synthesis 
Currently we have only achieved a partial synthesis of 2’-deoxy-6,3’-
propanouridine,  the rest of which is currently under investigation by Yiran Li in the 
McLaughlin lab. The synthesis begins with an isopropylidene protection of D-xylose. 
The resulting product was treated with 0.1 M HCl at 40oC for 1.5 hours to yield 1’,2’-
isopropylidene protected sugar (compound 4.1). This was followed by a selective 
protection of the 5’-hydroxyl by silane, which facilitated the oxidation at the 3’-hydroxyl 
(compound 4.2). The oxidation was carried out in DCM. The ratio of pyridine, 
chromium trioxide and acetic anhydride was critical for the success of the oxidation, and 
needed to be ensured. In this reaction compound 4.3 was generated as a ketone. The 
steps above are common for synthesis of both 2’-deoxy-6,3’-propanouridine and 2’-
deoxy-6,3’-butanouridine.  
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Figure 4.7 Synthetic pathway of 2’-deoxy-6,3’-propanouridine. Reaction conditions: i. 
POCl3/toluene, 110oC, 3h, 72.3%; ii. NaOMe/methanol:ether (3:1), rt. 16h, 94.9%; iii. 
CuSO4/acetone, rt. 24h, then 0.1M HCl, 40oC, 1h, 77.5%; iv. TBSCl/pyridine, rt. 3.5h, 
93.8%; v. CrO3-Pyridine-Ac2O (3eq: 10mL: 2.0mL)/DCM, rt. 3h, 72.9%; vi. Ethyl 
bromoacetate/Zn/THF, 45oC, 1h, 87.8%; vii. LAH/THF, rt. 30min, 76.0%; viii. 
CBr4/Ph3P/DCM, rt. 2h, 78.5%; ix. Compound 4.7/LDA/NaI/THF, -40oC, 1.5h, 41.3%. 
 
(Ethoxycarbonyl)-methyl was installed to the sugar moiety by Zinc catalyzed 
reaction of Compound 4.3 and ethyl bromoacetate. The resulting compound was reduced 
by LAH to yield compound 4.5 which contained a 3’-hydroxyethyl substitute group. 
Then carbon tetrabromide and triphenylphosphine were applied to substitute the 
hydroxyethyl into a bromoethyl group. Due to steric hindrance the 3’-hydroxyl would not 
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participate in this reaction. Here we got the sugar moiety ready for the sugar base cross 
coupling. Base moiety (compound 4.7), which was the other cross coupling partner, was 
achieved by chlorination followed by a methoxylation at C2 and C4 position. The base 
sugar cross coupling reaction was carried out at low temperature with the assistance of 
freshly made LDA. The resulting product (compound 4.8) was generated in an 
acceptable yield (41%), and proved to be the expected compound. 
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4.3 Discussion and future plan 
The future plan of this project includes the whole synthesis of both 2’-deoxy-6,3’-
propanouridine and 2’-deoxy-6,3’-butanouridine and their corresponding 
phosphoramidite which could be incorporated into DNA oligomers. The synthesis 
pathway will be followed as described (Fig. 4.8). The glycosylation reaction would set up 
the second connection between sugar and base; dehydroxylation would generate the 
modified deoxyuridine which is one of our target modified nucleosides. 2’-deoxy-6,3’-
butanouridine could be achieved similarly. At this stage the modified nucleosides could 
undergo a series of protection and phosphorylation to arrive at the appropriate stage to 
meet the requirements of the DNA synthesizer.  
 
Figure 4.8 Purposed future synthesis plan for 2’-deoxy-6,3’-propanouridine. 
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The resulting phoshporamidite would be incorporated into synthetic DNA 
oligomers, and thermal stability tests and structure tests would be done to evaluate the 
effect of introducting these novel modified nucleosides. 
4.4 Experimental 
All reactions were performed with flame-dried glassware under nitrogen in dry 
solvents unless indicated. Commercial available reagents were purchased from Sigma-
Aldrich, Acros, Oakwood, Lancaster, Chem-Impex International, Fisher, Chem Genes 
and Molekula. Silicycle silica gel (60 Å, particle size 40-63 µm) was used for flash 
chromatography and TLC Silica Gel with F-254 Indicator (60 Å, Silicycle) was used for 
TLC monitoring. TLCs were visualized by 260nm UV light and stained by 10% sulfuric 
acid. Anhydrous tetrahydrofuran (THF), diethyl ether (Et2O), N,N-dimethylformamide 
(DMF), pyridine (pyr), acetonitrile (MeCN), and dichloromethane (DCM) were obtained 
by using commercially available, pre-dried, oxygen-free alumina columns. Anhydrous 
ethanol (reagent alcohol) was purchased from Sigma-Aldrich and used directly. 
Anhydrous methanol was purified and dried by standard techniques and distilled prior to 
use.  NMR spectra were taken by Varian VNMRS400, VNMRS500, or INOVA 500 
instruments and calibrated using residual undeuterated solvent (CDCl3: δ H = 7.24 ppm, 
δ C = 77.23 ppm, DMSO-d6: δ H = 2.50 ppm, δ C = 39.51 ppm, Methanol-d4: δ H=3.31 
ppm, δ C = 49.15 ppm), and phosphorous 31P NMR was calibrated using external 
standard of 85% H3PO4 in water as 0.0ppm. Abbreviations of multiplicities were 
designated as follow: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. High-
resolution mass spectra (HRMS) were recorded on a Waters LCT or JEOL AccuTOF 
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mass spectrometer using ESI (electrospray ionization) or DART (direct analysis in real 
time).  UV spectra were acquired by a Beckman (Fullerton, CA) DU650 
spectrophotometer.   
 
 
Compound 4.1 
 
Commercially available compound D-xylose (20.0g, 133mmol) and anhydrous 
copper sulfate (27.0g, 169mmol) were dissolved in anhydrous acetone (250mL) at the 
ambient temperature. After cooled to 0oC, the reaction flask was slowly filled with 
concentrated sulfuric acid (2.50mL, 50.5mmol). Then the reaction flask was slowly 
warmed to the ambient temperature, and stirred for 36 hours. 0.1M hydrochloric acid 
(44.0mL) was added into the reaction mixture, and then the reaction was warmed to 40oC 
for 1 hour. After cooling to the ambient temperature, the reaction mixture was neutralized 
with saturated sodium bicarbonate. Insoluble copper sulfate was filtered off and washed 
with methanol. Filtrate was concentrated under reduced pressure and purified by flash 
chromatography (DCM/Methanol 90:10) to yield 1,2-O-isopropylidene-α-D-xylose 4.1 as 
yellow oil (19.7g, 77.5%). TLC Rf: 0.49 (silica gel, DCM/Methanol 90:10); 1H NMR 
(400 MHz, CDCl3) δ 5.69 (d, J=3.6Hz, 1H), 4.51 (d, J = 3.6 Hz, 1H), 4.31 (s, 1H), 4.04 - 
4.17 (m, 2H), 3.89 (d, J = 3.2 Hz, 1H), 3.46 (s, 1H), 2.48 (br, 1H), 1.46 (s, 3H), 1.31 (s, 
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3H); 13C NMR (100 MHz, CDCl3), δ 112.0, 105.1, 85.9, 78.7, 77.4, 61.6, 27.0, 26.4. 
HRMS (ESI-TOF) Calc. Mass for [M+H]+ 191.09195, found: 191.09215.  
 
 
 
Compound 4.2 
 
A mixture of 1,2-O-isopropylidene-α-D-xylose (5.6g, 29.4mmol) and tert-
butyldimethylchlorosilane was dissolved in pyridine (70.0mL) stirring at the ambient 
temperature for 3.5 hours. Volatiles were removed under reduced pressure, and the 
residue was taken up by ethyl acetate (250mL), washed with water (2×150 mL) and brine 
(200mL). The organic layer was dried over anhydrous Na2SO4, and then concentrated 
under reduced pressure and purified by flash chromatography (Hexanes/Ethyl acetate 
90:10) to yield compound 4.2 (8.4g, 93.8%) as yellow oil. TLC Rf: 0.24 (silica gel, 
Hexanes/Ethyl acetate 90:10); 1H NMR (400 MHz, CDCl3) δ 5.94 (d, J=4.0Hz, 1H), 4.49 
(d, J = 3.2 Hz, 1H), 4.35 (d, J=2.4 Hz, 1H), 4.31 (m, 1H), 4.11 (s, 1H), 4.09-4.12 (m, 2H), 
1.46 (s, 3H), 1.30 (s, 3H), 0.87 (s, 9H), 0.091(s, 3H), 0.087(s, 3H); 13C NMR (100 MHz, 
CDCl3), δ 111.7, 105.2, 85.8, 78.3, 77.4, 62.6, 27.1, 26.4, 25.9, 18.4, -5.29, -5.42. HRMS 
(ESI-TOF) Calc. Mass for [M+H]+ 305.17842, found: 305.17958.  
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Compound 4.3 
 
Compound 4.2 (6.2g, 20.4mmol) was dissolved in dichloromethane (20.5mL), 
and was added into previously prepared dichloromethane solution (100 mL) containing 
CrO3-Pyridine-Ac2O (5.88g, 3eq: 10mL: 2.0mL). The mixture was stirred at the ambient 
temperature for 3 hours, and then added dropwise to ethyl acetate (500mL) under stirring. 
The precipitate was filtered off and the filtrate was concentrated. The residue was 
chromatographed on silica gel (Hexanes/Ethyl acetate 95:5) to yield white solid 
compound 4.3 (4.5g, 72.9%). TLC Rf: 0.27 (silica gel, Hexanes/Ethyl acetate 95:5); 1H 
NMR (400 MHz, CDCl3) δ 6.11 (d, J=4.8Hz, 1H), 4.34 (m, 1H), 4.26 (d, J=4.4 Hz, 1H),  
3.78-3.88 (m, 2H), 1.44 (s, 3H), 1.43 (s, 3H), 0.84 (s, 9H), 0.037(s, 3H), 0.012(s, 3H); 13C 
NMR (100 MHz, CDCl3), δ 211.3, 114.4, 104.0, 82.0, 77.3, 64.2, 27.9, 27.4, 26.0, 18.4, -
5.30, -5.49. HRMS (ESI-TOF) Calc. Mass for [M+H]+ 303.16277, found: 303.16349.  
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Compound 4.4 
 
Compound 4.3 (1.2g, 4.0mmol) and fresh washed zinc powder (393mg, 6.0mmol) 
were suspended in THF (4.0mL). Ethyl bromoacetate (1.33mL, 12.0mmol) in THF (8mL) 
was slowly added to the reaction flask. After adding the reaction mixture was warmed to 
45 oC stirring for 1 hour. The reaction solution was cooled to the ambient temperature 
before quenched by saturated ammonium chloride. Volatiles was removed under reduced 
pressure, and the residue was taken up by dichloromethane (50mL), washed with water 
(3×30 mL) and brine (30mL). The organic layer was then concentrated and purified by 
flash chromatography (Hexanes/Ethyl acetate 90:10) to yield colorless oil compound 4.4 
(1.37g, 87.8%). TLC Rf: 0.34 (silica gel, Hexanes/Ethyl acetate 90:10); 1H NMR (500 
MHz, CDCl3) δ 5.78 (d, J=4.0 Hz, 1H), 4.67 (d, J=4.0 Hz, 1H), 4.16 (q, J=7.0 Hz, 2H),  
3.95 (t, J=5.0 Hz, 1H), 3.81 (qd, J1=11.0 Hz J2=4.0 Hz, 2H), 3.34 (s, 1H), 2.69 (d, J=15 
Hz, 1H), 2.41 (d, J=15 Hz, 1H), 1.57 (s, 3H), 1.35 (s, 3H), 1.26 (t, J=6.0 Hz, 3H) 0.87 (s, 
9H), 0.057(s, 6H); 13C NMR (100 MHz, CDCl3), δ 171.3, 113.0, 104.2, 82.8, 81.9, 78.0, 
61.4, 61.2, 37.3, 26.9, 26.8, 26.1, 18.5, 14.3, -5.14, -5.19. HRMS (ESI-TOF) Calc. Mass 
for [M+Na]+ 413.19660, found: 413.19820.  
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Compound 4.5 
 
Compound 4.4 (1.23g, 3.15mmol) was dissolved in THF (16mL), and cooled to 
0oC. A suspension of LAH (144.2mg, 3.8mmol) in THF (1.9mL) was added into 
compound 4.4 THF solution. The reaction was warmed to room temperature and stirred 
for 30 min. The excess of LiAlH4 was eliminated by adding THF/water (70: 30, 40ml). 
The mixture was filtrated through celite and concentrated. The obtained residue was 
purified by flash chromatography (DCM/Acetone 90:10) to yield compound 4.5 as 
colorless oil (834mg, 76.0%). TLC Rf: 0.38 (silica gel, DCM/Acetone 90:10); 1H NMR 
(500 MHz, CDCl3) δ 5.76 (d, J=3.5 Hz, 1H), 4.43 (d, J=3.5 Hz, 1H), 3.92 (m, 1H),  3.76-
3.85 (m, 4H), 2.95 (s, 1H), 2.61 (m, 1H), 1.97 (m, 1H), 1.57 (s, 3H), 1.35 (s, 3H), 0.88 (s, 
9H), 0.064 (s, 3H), 0.062 (s, 3H); 13C NMR (125 MHz, CDCl3), δ 112.8, 104.0, 83.4, 
81.4, 80.0, 61.6, 59.2, 32.8, 26.8, 26.7, 26.1, 18.5, -5.06, -5.19. HRMS (ESI-TOF) Calc. 
Mass for [M+H]+: 348.51232, found: 348.51029. 
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Compound 4.6 
 
Compound 4.5 (312mg, 0.90 mmol) was dissolved in dry DCM (6.0 mL) together 
with carbontetrabromide (663mg, 2.0 mmol). The reaction flask was flushed with 
nitrogen and cooled to 0 °C. A solution of triphenylphosphine (394 mg, 1.5 mmol) DCM 
(3.0 mL) was added slowly over 20 min to compound 4.5 solution. After addition, the 
reaction flask kept stirring at 0 °C for 1 hour, then warmed to the ambient temperature for 
2 hours. The reaction was quenched with water (0.5 mL), and then the volatiles were 
removed by rotary evaporator. Residue was taken up by DCM (40 mL), washed with 
water (3×20 mL) and brine (25 mL), and concentrated and purified by flash 
chromatography (Hexanes/Ethyl acetate 90:10) to yield product compound 4.6 as yellow 
oil (289mg, 78.5%). TLC Rf: 0.31 (silica gel, Hexanes/Ethyl acetate 90:10); 1H NMR 
(500 MHz, CDCl3) δ 5.79 (d, J=4.0 Hz, 1H), 4.36 (d, J=4.5 Hz, 1H), 3.85 (t, J=5.0 Hz, 
1H),  3.75-3.81 (m, 2H), 3.43-3.59 (m, 2H), 2.68 (s, 1H), 2.23-2.28 (m, 1H), 1.92-1.97 
(m, 1H), 1.56 (s, 3H), 1.35 (s, 3H), 0.88 (s, 9H), 0.067 (s, 6H); 13C NMR (100 MHz, 
CDCl3), δ 113.1, 104.1, 83.4, 81.0, 79.3, 61.3, 35.7, 27.1, 26.8, 26.7, 26.1, 18.5, -5.11,     
-5.21. HRMS (ESI-TOF) Calc. Mass for [M+H]+, found:. 
 
207 
 
 
Compound 4.7 
 
Commercial available thymine (1.26g, 10.0mmol) and Phosphoryl chloride (4.6 
mL, 50 mmol) were dissolved in dry toluene (25 mL), and then was added trethylamine 
(2.5 mL, 20 mmol). The reaction mixture was heated to reflux and kept for 3 hours. After 
reaction, the flask was cooled to room temperature and filled with ice water (20 mL). The 
organic layer was separated, and the aqueous layer was washed with toluene (2×50 mL). 
Then, the organic layers were combined and dried over anhydrous sodium sulfate. After 
filtration to remove Na2SO4, the organic layer was concentrated in a rotary evaporator to 
yield yellowish oil as crude. This crude intermediate was pure enough to be carried into 
following reactions: the crude was dissolved in 40 mL methanol/ether (methanol/ ether 
3:1). A 25% wt. NaOMe in methanol (6.25 mL, 4M) was slowly added into the reaction 
flask under stirring. The reaction kept stirring at the ambient temperature for 16 hours. 
After removing volatiles, the residue was mixed with water (10 mL), and then extracted 
with ether (3×50 mL). Organic layers were combined and concentrated to yield a crude 
product. The crude was applied with a flash chromatography (Hexanes/Ethyl acetate 
90:10) to yield compound 4.7 (1.18g, 76.5%) as white powder. TLC Rf: 0.21 (silica gel, 
Hexanes/Ethyl acetate 90:10); 1H NMR (500 MHz, CDCl3) δ 6.19 (s, 1H), 3.95 (s, 3H), 
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3.92 (s, 3H),  2.33 (s, 3H); 13C NMR (125 MHz, CDCl3), δ 172.1, 169.3, 165.4, 100.3, 
54.8, 53.8, 24.0. HRMS (ESI-TOF) Calc. Mass for [M+H]+ 155.08150, found: 155.08250. 
 
 
Compound 4.8 
 
Compound 4.7 (215 mg, 1.4 mmol) was suspended in THF (5.0 mL) at -78 °C. 
LDA (1.0 mL, 1.4 M) was slowly added to the suspension. Then the temperature was 
raised to -61 °C, and reaction solution was stirred for 45 min. After reaction mixture was 
added with NaI (10.5 mg, 0.07 mmol), compound 4.6 (290mg, 0.70 mmol) in THF (2.0 
mL) was slowly added into the reaction flask at -61 °C. Then the temperature was raised 
to -40 °C, and the reaction mixture was stirred for 1.5 hours. Thereafter, the reaction was 
quenched by saturated ammonium chloride and concentrated. Residue was applied to 
flash chromatography (Hexanes/Ethyl acetate 80:20) to yield compound 4.8 (141 mg, 
41.3%) as colorless oil. TLC Rf: 0.19 (silica gel, Hexanes/Ethyl acetate 80:20); 1H NMR 
(500 MHz, CDCl3) δ 6.16 (s, 1H), 5.69 (d, J=4.5 Hz, 1H), 4.29 (d, J=4.0 Hz, 1H), 3.93 (s, 
3H), 3.90 (s, 3H), 3.85 (m, 1H),  3.67-3.76 (m, 2H), 2.66 (s, 1H), 2.54-2.61 (m, 2H), 
1.73-1.92 (m, 2H), 1.54-1.60 (m, 1H), 1.53 (s, 3H), 1.33-1.41 (m, 1H), 1.30 (s, 3H), 0.83 
(s, 9H), 0.014 (s, 6H); 13C NMR (125 MHz, CDCl3), δ 172.4, 172.1, 165.5, 112.6, 104.1, 
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99.9, 83.7, 81.2, 78.9, 61.6, 54.7, 53.8, 37.7, 30.7, 26.7, 26.0, 22.0, 18.4, -5.15, -5.31. 
HRMS (ESI-TOF) Calc. Mass for [M+H]+ 485.26830, found: 485.26827. 
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1H NMR of Compound 4.1 
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13C NMR of Compound 4.1 
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13C NMR of Compound 4.2 
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1H NMR of Compound 4.4 
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13C NMR of Compound 4.5 
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1H NMR of Compound 4.8 
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